

AD-A239 442



AD _____

2

CONTRACT NO: DAMD17-86-C-6194

TITLE: MURAMYL PEPTIDE-ENHANCED SLEEP: PHARMACOLOGICAL
OPTIMIZATION OF PERFORMANCE

PRINCIPAL INVESTIGATOR: James M. Krueger

CONTRACTING ORGANIZATION: University of Tennessee, Memphis
Health Science Center
894 Union Avenue
Memphis, Tennessee 38163

REPORT DATE: June 1, 1991

TYPE OF REPORT: Annual Report

PREPARED FOR: U.S. ARMY MEDICAL RESEARCH AND DEVELOPMENT COMMAND
Fort Detrick, Frederick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for public release;
distribution unlimited

The findings in this report are not to be construed as an
official Department of the Army position unless so designated by
other authorized documents.

91 8 13 048

91-07739



DTIC
ELECTE
AUG 14 1991
S D D

REPORT DOCUMENTATION PAGE

OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.

1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE 1 June 1991		3. REPORT TYPE AND DATES COVERED Annual Report (6/1/90 - 5/31/91)	
4. TITLE AND SUBTITLE MURAMYL PEPTIDE-ENHANCED SLEEP: pharmacological optimization of Performance				5. FUNDING NUMBERS Contract No. DAMD17-86-C-6194 61102A 3M161102BS15.CD.033 WUDA310581	
6. AUTHOR(S) James M. Krueger					
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) University of Tennessee, Memphis Health Science Center 894 Union Avenue Memphis, Tennessee 38163				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Development Command Fort Detrick Frederick, Maryland 21702-5012				10. SPONSORING / MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES					
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for public release; distribution unlimited				12b. DISTRIBUTION CODE	
13. ABSTRACT (Maximum 200 words) It is now recognized that sleep results from neuronal activity which is regulated by the interactions of neurons with substances produced by neurons and other cellular components of the brain. Over the past 30 years, our technical abilities to identify and synthesize biochemicals has greatly improved; these advances have led to the identification of several endogenous sleep factors (SFs) (substances that promote sleep). Over the past five years of this contract, we have identified several new SFs and synthesized analogs that may be developed into new, more effective, and safer somnogenic agents. The broad goal of this USAMRDC-supported work has been to develop the information needed to determine if it is reasonable to propose either endogenous SFs or synthetic analogs as potential sleep-inducing agents for military use. To meet this goal, we previously reported our progress					
14. SUBJECT TERMS Sleep; Muramyl Peptide; Tumor Necrosis Factor; Fever; Cholesty- stokinin; Infection; EEG; Growth Hormone Releasing Hormone; RAIIT; Stress; Lab Animals; Rabbits				15. NUMBER OF PAGES	
				16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited		

ABSTRACT (#19 continued)

on 21 sets of experiments; this year, an additional 5 sets of experiments were performed. Briefly we found: 1) That several synthetic fragments of tumor necrosis factor α that contain the TNF₃₁₋₃₆ sequence are somnogenic. A patent application has been filed on this discovery; 2) We also showed for the first time that the cell walls of archaebacteria (pseudomurein) have biological activity in mammals; 3) We found that prostaglandin D₂ or E₂ failed to greatly affect rabbit sleep suggesting that sleep altering abilities of these substances are species specific; 4) We showed that cholecystokinin elicits sleep in rabbits; this hormone is probably responsible for the feelings of sleepiness after a meal; 5) Finally, we began a series of studies examining on a cellular level, how various SFs alter the expression of surface antigens on brain cells. Our results are discussed within the context of a theory on sleep regulation.

This report is the fifth and last annual report under our current USAMRDC contract. The progress we have made over the past five years under the auspices of this contract will probably revolutionize the way we think about sleep. The details of this progress will be provided in the final report, but a brief list of our major findings is provided here:

- 1) We showed for the first time that sleep is, indeed, altered over the course of infectious disease.
- 2) We determined for bacteria what microbial components (and their chemical structural requirements) drive sleep responses (muramyl peptides and endotoxin).
- 3) We have learned much about which endogenous products induced by the microbial agents are responsible for sleep responses.
- 4) We have begun to describe on a cellular level how these endogenous SFs affect brain cells.
- 5) We have developed several completely new somnogenic agents based on the chemical structures of endogenous SFs; two patents have been applied for.
- 6) Finally, we have developed a theory of brain organization in regard to sleep regulation and theorized how various SFs interact with each other forming regulatory feedback loops that regulate sleep.

Some of this progress has been theoretical, but much has also been very practical. From the view point of pharmacological enhancement of performance, it seems likely to us that the new synthetic somnogenic agents we discovered can be developed into usable sleep-inducing agents.

FOREWORD

In conducting the research described in this report, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Animal Resources, National Research Council [DHEW Publication No. (NIH) 78-23, Revised 1978].

Citations of commercial organizations and trade names in this report do not constitute an official Department of the Army endorsement or approval of the products or services of these organizations.

TABLE OF CONTENTS

Summary.	ii
Foreword	iv
Introduction	1
Methods.	4
Specific Experimental Protocols.	7
Results.	17
Experiment No. 1.	17
Experiment No. 2.	20
Experiment No. 3.	22
Experiment No. 4.	23
Experiment No. 5.	25
Discussion	28
References	51
Tables	76
Figures.	87
Distribution List.	103

Accession For	
NTIS	CR221
DTIC	TAB
Unannounced	
Justification	
By	
Distribution/	
Availability Codes	
Dist	Availability Codes
A-1	



LIST OF TABLES

Table 1	Effects of $TNF\alpha$, $TNF\beta$, $TNF\beta$ fragments and FMLP peptides on rabbit sleep-wake activity and brain temperatures	76
Table 2	Effects of IV injection of pseudomurein or microspheres on rabbit SWS, REMS, EEG delta voltage and T_{co}	78
Table 3	Effects of PGE_2 on rabbit sleep	79
Table 4	Effects of PGD_2 on rabbit sleep	80
Table 5	Effects of CCK injection on maximal EEG delta-wave amplitude during NREMS	81
Table 6	Summary of effects of substances tested on HLA_{DR} expression	82
Table 7	List of putative sleep factors	85
Table 8	Criteria for NREMS factors with regard to physiological sleep	86
Table 9	Criteria for sleep factors	86

LIST OF FIGURES

Fig. 1:	Effects of IV injection of pseudomurein on rabbit SWS, REMS, EEG-delta wave voltage and brain temperature	87
Fig. 2:	Effects of ICV injection of PGE ₂ on brain temperature of rabbits	88
Fig. 3:	Effects of ICV injection of PGE ₂ on NREMS and REMS	89
Fig. 4:	Effects of ICV injection of PGD ₂ on NREMS and REMS	90
Fig. 5:	Effects of IP injections of CCK on sleep-wake activity and brain temperature	91
Fig. 6:	Effects of ICV injection of CCK on sleep-wake activity and brain temperature	92
Fig. 7:	Growth curves of glioblastoma cell lines HTB14, HTB16, and HTB17	93
Fig. 8:	IFN γ -induced HLA _{DR} expression	94
Fig. 9:	Time course of IFN γ -induced HLA _{DR} expression	95
Fig. 10:	TNF α amplifies IFN γ -induced HLA _{DR} expression	96
Fig. 11:	Time course of TNF α effects on IFN γ -induced HLA _{DR} expression	97
Fig. 12:	TGF β 1 inhibition of IFN γ -induced HLA _{DR} expression	98
Fig. 13:	TGF β 2 inhibition of IFN γ -induced HLA _{DR} expression	99
Fig. 14:	IL1 β inhibition of IFN γ -induced HLA _{DR} expression	100
Fig. 15:	Activational system for sleep	101
Fig. 16:	Interaction of sleep factors with neuronal sets	102

ABBREVIATIONS

aCSF	artificial cerebrospinal fluid
BSA	bovine serum albumin
CCK	cholecystokinin
CNS	central nervous system
CSE	control standard endotoxin
DMSO	dimethyl sulfoxide
DSIP	delta-sleep inducing peptide
EEG	electroencephalographic
ELISA	enzyme linked immunosorbant assay
FBS	fetal bovine serum
FITC	fluorescein isothiocyanate
GFAP	glial fibrillary acidic protein
GH	growth hormone
GRF	growth hormone releasing hormones
GSSG	oxidized glutathione
HLA	human leukocyte antigen
ICAM	intercellular adhesion molecule
ICV	intracerebroventricular
IL1	interleukin-1
IP	intraperitoneal
IV	intravenous
LAL	limulus amoebocyte lysate
LPS	lipopolysaccharide
MDP	muramyl dipeptide
MEM	minimal essential medium
MHCII	major histocompatibility complex class II
NREMS	non-rapid-eye-movement sleep
OD	optical density
PFS	pyrogen-free saline
PG	prostaglandin
PGD ₂	prostaglandin D ₂
PRL	prolactin
REMS	rapid-eye-movement sleep
rhIFN γ	recombinant human interferon γ
RIA	radioimmunoassay
5-HT	serotonin
SF	sleep factor
SRIF	somatostatin
SWS	slow-wave sleep
T _{br}	brain temperature
T _{co}	colonic temperature
TGF	transforming growth factor
TNF	tumor necrosis factor
VIP	vasoactive intestinal peptide
W	wakefulness

INTRODUCTION

The causes of sleep have been intensely debated for the past two or more millennia. Hippocrates concluded that sleep results from the retreat of blood and warmth into the body's inner regions. Aristotle proposed an alternative hypothesis that captured the minds of Europeans for nearly 2,000 years. He proposed that vapors arising from food digesting in the stomach were transported throughout the body via the humors, thereby inducing sleep. Aristotle's idea provides the fundamental concept of sleep factors (SFs); that a change in the amount of some substances(s), in response to a physiological process, acts to promote sleep. Of course the specifics of what is changed, what induces the change, where it happens, etc. have changed over the years and still remain in debate.

Our modern views of the causes of sleep began early in the twentieth century. Legendre and Pieron (114) experimentally addressed the hypothesis that the brain produces, during wakefulness (W), substances that induce sleep. To investigate this hypothesis, cerebrospinal fluid from sleep-deprived dogs was transferred into normal dogs. The recipient animals were then observed to sleep longer than usual. They concluded that a "hypnotoxin" (SF, sleep-inducing substance) was present in the cerebrospinal fluid. Although the chemical nature of the hypnotoxin described by Legendre and Pieron was not determined. These experiments, as well as similar experiments published by Ishimori in Japanese (1909) about the same time, established the fundamental observations to which others in the latter half of this century were to return.

By the 1920s, a new line of inquiry began to dominate the field concerned with sleep regulation. These new hypotheses emphasized the dominant role that neurons and their dynamic patterns of electrical impulses play in sleep regulation. About sixty years ago, these neurophysiological theories of sleep regulation received a major boost when von Economo (183) correlated lesions produced by a viral infection in the hypothalamus to sleep disturbances; when the lesions were in the anterior hypothalamus, patients were insomniacs. Von Economo used these data to postulate that the anterior hypothalamus is involved in sleep regulation and that sleep results from active neural processes within the brain rather than from the simple withdrawal of neural stimulation (a massive amount of subsequent data support both of these hypotheses). Ironically, although an infectious disease (von Economo's virus) played an important role in the support of neural theories of sleep, the connections between the sleepiness that is symptomatic of nearly all infectious diseases and the hypnotoxin theories of sleep were not made for another 60 years. Throughout this time, the neurophysiological theories of sleep regulation rapidly evolved in sophistication and detail in parallel with the explosive growth in knowledge and techniques available in electrophysiology.

More recently, there also has been an impressive growth in our technical ability to isolate and detect biochemicals. These advances have led to the recognition that neurons and glial cells produce, transport, package, release, and respond to a large numbers of biochemicals. Some of these substances change the patterns of electrical activity of neurons and also induce sleep. As a consequence, today these previous, seemingly dichotomous theories of sleep regulation, the hypnotoxin and

neural theories, are now viewed as complementary to each other. Furthermore, these advances in biochemical techniques have led to the intense pursuit of SFs over the past twenty years and resulted in the identification of several SFs. These results suggested to us that new, safer and effective somnogenic agents can be developed. Thus, the major objective of our USAMRDC-supported work has been to develop information needed to determine if it is reasonable to propose either endogenous SFs or synthetic analogs as potential sleep-inducing agents. As part of this goal, we have initiated the process to obtain patents on two different classes of somnogenic compounds.

With the above objective in mind, in the first year of our contract period (June 1, 1986 - May 30, 1987), five sets of experiments were performed; in the second year (June 1, 1987 - May 30, 1988) six sets of experiments were carried out; in the third year (June 1, 1988 - May 30, 1989) five sets of experiments were performed and in the fourth year (June 1, 1989 - May 30, 1990) five sets of experiments were reported. Results from those experiments are described in our annual reports dated June 1, 1987; June 1, 1988; June 1, 1989 and June 1, 1990. This year, June 1, 1990 - May 30, 1991 five sets of experiments were performed; they are numbered one through five as follows:

- 1) In the first experiment, we show that several synthetic fragments of tumor necrosis factor (TNF) α that contains the TNF₃₁₋₃₆ sequence are somnogenic. (A patent application for this discovery has been filed).
- 2) Second, we showed that the cell walls (pseudomurein) of an archaeobacteria (*Methanobacterium thermoautotrophicum*) has biological activity (sleep promoting) in mammals.

3) Third, we showed that neither prostaglandin (PG)E₂ or PGD₂ were somnogenic in rabbits thus suggesting that the somnogenic actions of these agents are species specific.

4) Fourth, we showed that cholecystokinin (CCK) elicits sleep in rabbits. This hormone is released after food intake thus suggesting that it may be responsible for the feelings of sleepiness after eating.

5) Finally, we described how the expression on astrocytes of major histocompatibility class II antigen is altered by a variety of somnogenic agents.

METHODS

Animals. Male New Zealand White Pasteurella-free rabbits (3-4 kg) were provided with a lateral cerebral ventricular guide cannula, a brain thermistor and stainless steel screw electroencephalographic (EEG) electrodes as previously described (102, 139, 145). A calibrated thermistor, (50 k Ω , model 4018, Omega Engineering, Stanford, CT) was implanted through a burr hole in the skull over the parietal cortex to measure brain temperature (T_{br}). EEG electrodes were placed over the frontal and parietal cortices. The leads from the EEG electrodes and the thermistor were led to an Amphenol plug; the wires, electrodes, and guide tube were held in place with dental acrylic (Duz-All, Coralite Dental Products, Skokie, IL). Animals were allowed to recover from the surgery two or more weeks.

The rabbits were kept on a 12:12 hr light:dark cycle (light on at 0600 hr) at $21^{\circ} \pm 1^{\circ}\text{C}$. Rabbits were placed in the recording chambers

(Hotpack 352600, Philadelphia, PA) for at least two 24 h habituation sessions before recordings were taken from animals for the first time. When recordings were taken from animals, they were placed in the experimental chambers the preceding evening. The light:dark schedule and ambient temperatures of the recording chambers were kept the same as that of the housing facility. Food and water were available *ad libitum*.

Recordings and sleep analyses. A flexible tether connected an electronic swivel to the Amphenol connector on the rabbit head, this apparatus was suspended by a shock-absorbing system; this allowed the animals to have relatively complete freedom of movement within the experimental cages. To detect body movements, ultrasonic motion detectors were used. Cables from the motion detectors and the electronic swivel were connected to Grass 7D polygraphs in an adjacent room. EEG, T_{br} , and movement were recorded on the polygraphy paper. In addition, the EEG signal was led through two band pass filters, (0.5-3.5 Hz δ and 4.0-7.5 Hz θ) the signals were rectified and the ratio of θ/δ activity was continuously computed and recorded on the polygraph paper simultaneously with the EEG, T_{br} and body movements. This θ/δ ratio served as an aid in identifying periods of rapid-eye movement sleep (REMS) (139). T_{brs} were also recorded using a data logger (Acrosystem 400, Beverly, MA); values taken every 10 min were stored on computer disks.

Vigilance states were identified as previously described (139). Non REMS (NREMS) (also called slow wave sleep [SWS] in this report) was associated with decreasing T_{brs} , low EEG θ/δ ratio and a high amplitude EEG. In contrast, REMS was characterized by a rapid rise in T_{br} upon entry into REMS, high θ/δ ratios and a relative low-amplitude EEG. Polygraph records were visually scored in 12 sec epochs (102). The

duration of a particular sleep or wake episode was measured by entering episode lengths (distances on the recording paper) into a computer with a calibrated digitizer board (Jandel Scientific). The percentages (duration) of NREMS and REMS were calculated for 1 and 6 hr periods. Differences between results obtained on experimental days and control days were evaluated by use of the Wilcoxon matched-pair signed rank test. The Kruskal-Wallis one way analysis by ranks were used to determine dose dependency effects.

Test substances were dissolved in small volumes of dimethyl sulfoxide (DMSO) or ethanol; aliquots of those preparations were diluted with artificial cerebrospinal fluid (aCSF) (2 mM KCl, 1.15 mM CaCl_2 and 0.9 mM MgCl_2 in pyrogen free saline, 115 mM NaCl, Abbott, Chicago, IL) such that the doses used were in 25 μl . For control experiments and equal amounts of aCSF containing DMSO or ethanol was used as injectant. These recordings were obtained from the same animal thus a matched-pairs design was used. Most substances were injected into a lateral cerebral ventricle (intracerebroventricular, ICV). Injection volume was 25 μl ; each injection took about 2 min. In the case of CCK, it was also injected IP. Finally, suspensions of pseudomurein were injected IV before recordings began. Rabbits were injected between 0845 and 0915 hr. After injections, animals were returned to the experimental cages and were recorded from for the next 6 hr.

Specific Experimental Protocols

Experiment No. 1: Somnogenic activity of TNF fragments.

Compounds tested. Human recombinant TNF α (hu r TNF α) and hu r TNF β were obtained from R & D Systems, Inc., Minneapolis, MN, TNF α peptides 10-69 and 140-157 were gifts from Dr. Louis Chedid (University of South Florida). TNF α peptides 10-36, 31-45, 46-65, 31-68, 44-68, 31-45, 45-65, 69-100, and 101-135 were synthesized by Dr. Jerome Seyer. FMLP was purchased from Sigma Chemical Co., (St. Louis, MO). Peptides were dissolved in small volumes of DMSO before being diluted with aCSF for ICV injection.

Experiment No. 2: Somnogenic activity of pseudomurein.

Materials. Lyophilized *Methanobacterium thermoautotrophicum* was a gift from O. Kandler and W. König. Pseudomurein was isolated as described before for staphylococcal cell walls (77, 111). Briefly, whole cells were disintegrated by shaking the cell suspension with glass beads in a cell mill. Membranes and proteins were removed by successive treatment of the cell walls with EDTA, Triton X-100, and trypsin. Possible other contaminants were removed by treatment with trichloroacetic acid. After extensive washing the cell walls were lyophilized.

In preparation for IV injection into rabbits, the lyophilized pseudomurein was suspended in appropriate volumes of pyrogen free saline (PFS) (0.9% NaCl, Abbott, North Chicago, IL, USA) to provide the desired concentrations (Table). One ml of sample or vehicle alone was injected into a marginal ear vein. In some cases it was suspended in PFS containing 1 mg/ml Polymyxin B sulfate (Sigma, St. Louis, MO, USA) and pre-

incubated for one hour at 37°C prior to the injection to inactivate possible endotoxin contamination.

In a separate control experiment polybead polystyrene microspheres (0.98 μm diameter, 2.5% solids = 5×10^{10} spheres/ml, Polysciences, Warrington, PA, USA) were diluted to 5×10^9 /ml in PFS before IV injection.

Amino acid analysis of the pseudomurein sample was performed by Dr. Jerome M. Seyer (Veterans Administration Medical Center, Memphis, TN) to verify the purity of the sample. Conforming with the known structure of pseudomurein (95), only three amino acid were detected: alanine (2.08 nmol/ μg pseudomurein), glutamic acid (1.84 nmol/ μg), and lysine (1.79 nmol/ μg). No other amino acids were found at a sensitivity that would have detected < 50 pmol/ μg . Amino sugars could not be identified under the conditions used.

The Limulus Amoebocyte Lysate assay (LAL, sensitivity 0.25 EU/ml) and Control Standard Endotoxin (CSE, E. coli 0113, Associates of Cape Cod, Woods Hole, MA) were used to test samples for endotoxin contamination and to determine the amount of Polymyxin B sulfate necessary to neutralize the minimal LAL reactivity detected in the pseudomurein samples.

A within subject experimental design was used: experimental and control recordings were obtained from the same rabbits on different days. Controls for pseudomurein or microsphere samples were injected with PFS, controls for pseudomurein plus polymyxin samples received a solution of 1 mg/ml polymyxin B in PFS which was pre-incubated at 37°C for 1 h prior to injection. Average hourly values were used to evaluate

effects across the six hour recording period by means of the the Wilcoxon matched-pairs signed-ranks test.

Experiment No. 3: Back of somnogenic activity of PGE₂ and PGD₂.

Compounds tested. PGD₂ was obtained from Sigma Chemical Co. (St. Louis, MO) and from Cayman Chemical Co. (Ann Arbor, MI). Two different lots of PGD₂ were obtained from Cayman Co. Results obtained using these two lots and those obtained using the Sigma preparation did not differ from each other and thus were pooled when appropriate. The ability of the PGD₂ used to bind with antibodies used in radioimmunoassays (RIA) was determined using either the RIA method described by Leffler (Department of Physiology, University of Tennessee, Memphis) or using a commercially available RIA PGD₂ kit obtained from Advanced Magnetics, Inc. (Cambridge, MA). In both cases, the antibodies bound the PGD₂ preparation providing indirect evidence that the chemical form of the PGD₂s tested were indeed PGD₂. PGE₂ was obtained from Sigma Chemical Co.

Experimental Protocols. PGE₂ or PGD₂ were dissolved in small volumes of ethanol (10 mg/0.1 ml ethanol). Small aliquotes of these stock solutions were added to pyrogen free saline (PFS) (0.01-70.5 ml/1.0 ml PFS) in preparation for injection into animals. Twenty five μ l of these solutions were injected ICV over a 1 min period beginning at 0830 hr under sterile conditions. For control studies, vehicle containing equal amounts of ethanol were used as injectants on different days. The small amount of ethanol used in this study did not affect sleep compared to using PFS alone (data not shown). After ICV injections, animals were connected to the electronic swivels then recorded from for the

next six hours. Estimated range of time between the end of injection and the beginning of recording was 5-15 min. In one case, when 0.25 nmol of PGD₂ was used, 75 µl of solution was infused slowly over a 45 min period into a lateral ventricle; this slower method of administration was used to replicate the methods used in a previous preliminary study (100). The percentages (duration) of NREMS and REMS were calculated for 12 min periods during the first postinjection hour and for 1 and 6 hr periods. Differences between results obtained on experimental days and control days were evaluated across the 6-h recording periods by the Friedman's nonparenetic two-way analysis of variance and within discrete time blocks by use of the Wilcoxon matched-pairs signed-ranks test. The Kruskal-Wallis one way analysis of variance by ranks was used to determine dose related effects. All analyses were performed by the SPSS^x international analysis system and an alpha level of $p \leq 0.05$ was accepted as indicating significant departure from control.

Experiment No. 4: Somnogenic effects of CCK in rabbits.

On the experimental days, the rabbits were injected intraperitoneal (ip) or ICV with saline (control) or CCK-octapeptide sulphate ester (Bachem Inc., Torrance, CA) dissolved in isotonic saline. The injections were done between 0845 and 0915 h. The volume of the ip injection was 2 ml/kg. Each ICV injection (25 µl/rabbit) lasted for 1 min and an additional min was allowed before removing the injection cannula. After the treatments the sleep-wake activity and T_{br} were recorded for 6 h. Three doses were tested ICV: 0.05 µg/rabbit, 0.5 µg/rabbit, 2 µg/rabbit, three different doses were injected IP: 2.5 µg/kg, 10 µg/kg, 40 µg/kg. The experimental protocol followed a self-control design,

, i.e., each rabbit received saline treatment (control day) and 1-3 treatments of the various CCK doses. The differences between the effects of CCK and the saline injection were calculated. The experiments were separated by at least 2 days.

The durations of vigilance states were calculated hourly, and were expressed as average percent of time (\pm SE). These hourly values after CCK and saline injections were compared across 6 h by two-way ANOVA followed by an hour-by-hour comparison by paired Student's t-test. The maximal delta amplitudes during NREMS were compared after CCK and saline treatment in the first postinjection h by paired Student's t-test. The temperature data were averaged in 10 min intervals (\pm SE). Comparisons were made between the effects of saline and CCK injections for the first 3 postinjection h by two-way ANOVA. A p value < 0.05 was taken to indicate significant difference.

Experiment No. 5: Modulation of human leukocyte antigen DR expression in glioblastoma cells by putative sleep factors.

Reagents. Recombinant human IFN γ (rhIFN γ) was purchased from Boehringer Mannheim Biochemicals (Indianapolis, IN) with activity $> 2 \times 10^7$ units (U)/mg in an EMC virus/WISH cell assay. Human IFN α was purchased from Chemicon (Temecula, CA) with activity of 10^6 U/mg. The following cytokines and antibodies were purchased from R&D Systems (Minneapolis, MN) and their activities were determined by R&D Systems as indicated; a) recombinant human TNF α (rhTNF α), activity $\geq 2 \times 10^6$ U/mg measured by its cytolytic effect on L929 cells; b) recombinant human IL-1 β (rhIL-1 β), activity $\geq 5 \times 10^8$ U/mg in a Lymphocyte Activation Factor assay; c) porcine transforming growth factor (TGF) β 1 and β 2, ED $_{50}$

for the inhibition of ^3H -thymidine incorporation in mink lung epithelial cells was 0.05 ng/ml; d) the neutralizing doses₅₀ (ND₅₀) of antibodies against porcine (TGF β) raised in chicken were 2-3 mg/ml for blocking the effect of TGF β 1 at a dose of 0.5 ng/ml; ND₅₀ of antibodies against TGF β 2 raised in rabbit was 1-2 mg/ml for blocking the effect of TGF β 2 at a dose of 0.25 ng/ml; the ND₅₀ of antibodies against rhTNF α was 0.2 mg/ml for blocking the effect of rhTNF α at a dose of 0.25 ng/ml. Serotonin (5-HT), PGE₂, PGD₂, and hydrocortisone were purchased from Sigma Chemical Co. (St. Louis, MO). Vasoactive intestinal peptide (VIP) was obtained from Bachem, Inc. (Torrance, CA). Delta sleep-inducing peptide (DSIP) was purchased from Peninsula Laboratories, Inc. (Belmont, CA). Muramyl dipeptide (MDP) was a gift from Dr. L. Chedid.

Cell Culture

Cell growth. Three human glioblastoma cell lines, HTB14, HTB16 and HTB17, and a human neuroblastoma cell line HTB11 were purchased from American Type Culture Collection (Rockville, MD). Cells were grown in 100 x 15 mm tissue culture dishes in modified Eagle's minimum essential medium (MEM) (Flow Laboratories, Inc., McLean, VA) supplemented with 5% fetal bovine serum (FBS) (Biocell, Carson, CA), and 100 IU/ml penicillin G and 100 mg/ml streptomycin (Sigma Chemical Co.) at 37°C in an atmosphere with 5% CO₂ in air. Cells in confluent culture were incubated with 0.25% trypsin solution for 1-2 min, resuspended in fresh culture medium, and about 2.5×10^3 cells/well were transferred to 96-well plates. Cell number in each of 6 wells was counted every day for up to 11 days, and cells in parallel wells were digested with 30 ml of 0.6N .

NaOH overnight and then the protein amount in each well was determined using BCA protein assay kit (Pierce, Rockford, IL).

Immunofluorescence staining for glial fibrillary acidic protein (GFAP) and neurofilament.

Glioblastoma cells were stained for GFAP, a unique intracellular interfilament for astrocytes. Confluent cell cultures in 100 x 15 mm dish were trypsinized and 4×10^4 cells were transferred to 12-well plates with a round glass coverslip in each well, and incubated at 37°C, with 5% CO₂ in air for 2 days. As previously described (122), cells were rinsed twice with medium and fixed with 3.8% formaldehyde at room temperature for 5 min following 6 brief (about 1/2 sec.) immersions in acetone at -20°C. Then cells were incubated 4 hours at room temperature with 500 µl of polyclonal rabbit anti-human GFAP (Sigma Chemical Co.) diluted 1:200 in culture medium as the primary antibody. After washing 5 times with PBS containing 0.1% bovine serum albumin (BSA), cells were incubated in the dark for one hour with goat anti-rabbit IgG-conjugated to fluorescein isothiocyanate (FITC) (HyClone Laboratories, Inc., Logan, UT) diluted 1:100 in 1% BSA-PBS as the secondary antibody. Finally, coverslips were mounted on slides with 1:1 PBS:glycerol before microscopic examination. The procedures for staining neurofilament was the same as to that for GFAP except that the primary antibody was monoclonal mouse anti-human neurofilament (Dakopatts, Carpinteria, CA) and the secondary antibody was goat anti-mouse IgG-conjugated to FITC (Sigma Chemical Co.).

Experimental Design

Experiment A: Expression and induction of HLA_{DR} by rhIFN γ on glioblastoma and neuroblastoma cells

HLA_{DR} expression and the effects of rhIFN γ on HLA_{DR} expression were determined in all three glioblastoma cell lines HTB14, HTB16 and HTB17, and the neuroblastoma cell line HTB11. To obtain confluent cultures within 1-2 days, cell suspensions containing $2-3 \times 10^4$ cells were added into 96-well culture plates. At the beginning of an experiment, the original medium was aspirated off, and either 200 μ l of fresh medium or media containing various concentrations of rhIFN γ (10^{-1} , 1, 10, 10^2 , 10^3 , 5×10^3 , and 10^4 U/ml) were added to individual wells. Each treatment for each dose of rhIFN γ was performed in 6 replicate wells. Culture plates were incubated at 37°C with 5% CO₂ for 4 days. HLA_{DR} expression on the cell surface was determined using an enzyme linked immunosorbant assay (ELISA) method on the whole cells as described below. To determine the effects of IFN γ on HLA_{DR} expression over time, HTB16 cells were treated with 1000 U/ μ l of rhIFN γ . The culture media with rhIFN γ was removed on the fifth day and replaced with 200 μ l of fresh culture medium. HLA_{DR} expression was assessed every day in triplicate samples from day 0 to day 9.

Experiment B: Effects of cytokines TNF α , TGF β 1 and β 2, IL-1 β on HLA_{DR} expression in HTB16 cells.

Cell culture preparation was the same as that for experiment A; each treatment was performed in 6 wells.

I. rhTNF α

HTB16 cells were treated with 0.1, 1, 10, 50, and 250 ng/ml of rhTNF α diluted in fresh medium or in the media containing a fixed dose of rhIFN γ (100 U/ml or 500 U/ml) for 4 days to determine effects of TNF α doses on IFN γ -induced HLA DR expression. To determine the effects of TNF α on IFN γ -induced HLA DR over time, cells were incubated with 10 ng/ml of rhTNF α combined with 100 U/ml of rhIFN γ for 8 days; HLA DR expression was quantitated every day. Cells were also treated with neutralizing antibody against rhTNF α at concentrations of 10, 20, and 40 $\mu\text{g/ml}$ in combination with 10 ng/ml of rhTNF α and 100 U/ml of rhIFN γ for 4 days in order to verify that the effects of TNF α were specific.

II. TGF β 1 and β 2

HTB16 cells were treated with 0.01, 0.1, 1, and 10 ng/ml of TGF β 1 and β 2 diluted in fresh medium and in the media containing 100, 500, and 1000 U/ml of rhIFN γ respectively for 6 days to determine the effects of TGF β 1 and β 2 doses on IFN γ -induced HLA DR expression. The effects of TGF β 1 and β 2 on IFN γ -induced HLA DR over time were carried out over 8 days; cells were incubated with 10 ng/ml of either TGF β 1 or β 2 in combination with 100 U/ml of rhIFN γ and HLA DR expression was quantitated every day. To block the inhibitory effect of exogenous TGF β 1, cells were treated with neutralizing antibody against TGF β at concentrations of 1, 5, 10, and 25 $\mu\text{g/ml}$ in combination with 10 ng/ml of TGF β 1 and 100 U/ml of rhIFN γ for 6 days. A similar experiment was carried out for TGF β 2 using the same doses of neutralizing antibody against TGF β 2 but combined with three different treatments of TGF β 2 and rhIFN γ : a) 1

ng/ml of TGF β 2 plus 100 U/ml of rhIFN; b) 1 ng/ml of TGF β 2 plus 500 U/ml of rhIFN γ ; and c) 10 ng/ml of TGF β 2 plus 500 U/ml of rhIFN γ .

III. IL-1 β

To examine the effects of interleukin-1 β (IL-1 β) on HLA α _{DR} expression and on IFN γ -induced HLA α _{DR} expression, HTB16 cells were treated with rhIL-1 β using concentrations of 0.5, 2, 10, 50, and 250 pg/ml in the absence or presence of 500 U/ml of rhIFN γ for 4 days before HLA α _{DR} expression was assessed.

Experiment C: Effects of PGE₂, PGD₂, IFN α , VIP, DSIP, 5-HT, hydrocortisone, and MDP, on HLA α _{DR} expression in HTB16 cells.

HTB16 cells were treated with the following: PGE₂, PGD₂, IFN α , VIP, DSIP, 5-HT, and hydrocortisone. All agents were incubated with cells in the absence or presence of 500 U/ml of IFN γ for 4 days before HLA α _{DR} expression was assessed. The doses for these substances used were PGE₂ and PGD₂, 10⁻⁹, 10⁻⁸, 10⁻⁷, 10⁻⁶, and 10⁻⁵ M; IFN α , 1, 10, 10², and 10³ U/ml; VIP, DSIP, and 5-HT, 10⁻⁸, 10⁻⁷, 10⁻⁶, and 10⁻⁵ M; and hydrocortisone, 10⁻⁵, 10⁻⁴, and 10⁻³ M. MDP was tested using doses of 0.02, 0.2, 2, and 20 mM in the absence and presence of 500 U/ml of IFN γ ; incubations were 7 days. Each treatment was performed in 6 independent wells.

Quantitative analysis of cell surface HLA α _{DR} expression using ELISA

After the experimental treatments described above, media were aspirated off and cells were fixed with 100 μ l of 3.8% formaldehyde at room temperature for 5-7 min. After rinsing with culture medium twice,

100 μ l of monoclonal mouse antihuman HLA_{DR} antibody (Dakopatts) diluted 1:200 in culture medium was applied into designated wells and the plate was incubated at 4°C overnight. The plate was then washed gently with 300 μ l of 0.1% BSA-PBS three times. The next incubation with 200 μ l of secondary antibody, goat anti-mouse IgG-conjugated to horseradish peroxidase (Pierce) diluted 1:4000 in 1% BSA-PBS, was carried out at room temperature for 2 hours. Following three washes with 0.1% BSA-PBS, 100 μ l of peroxidase substrate solution containing 2,2'-azino-di[3-ethyl-benzthiazoline sulfonate] (Kirkegaard & Perry Laboratories, Inc., Gaithersburg, MD) was placed into each well. After 40 to 50 min, the optical density (OD) was read at 405 nm by a Microplate Autoreader (Bio-Tek Instruments, Inc., Winooski, VT). Finally, the cells in each well were digested with 30 μ l of 0.6N NaOH overnight, and the amount of protein in each well was determined using BCA assay reagents (Pierce). The HLA_{DR} expression is presented as OD/mg protein.

RESULTS

Experiment No. 1:

I. TNF α

TNF α elicited a dose-dependent increase in NREMS and T_{br}. The threshold dose for both the hypnogenic and pyrogenic effects was 0.05 μ g. This dose of TNF α induced a significant increase in NREMS across the 6 h experimental period (Table 1). Most of the TNF α -induced excess NREMS occurred during postinjection hours 2-4 (Fig. 1) although sleep tended to be elevated for the next two hours as well. Injection of 0.5

μg and 5 μg $\text{TNF}\alpha$ promoted NREMS for a more prolonged period extending to the sixth postinjection hour elicited an overall increase in NREMS across the 6 h recording period (Table 1). However, neither the 0.005 nor 0.05 μg dose of $\text{TNF}\alpha$ altered REMS. The effects of $\text{TNF}\alpha$ on REMS were not dose-related. REMS was significantly reduced after the injection of the two higher doses. $\text{TNF}\alpha$ -induced changes in T_{br} paralleled the $\text{TNF}\alpha$ -induced NREMS effects; there was a significant correlation between the pyrogenic effects and hypnogenic effects of $\text{TNF}\alpha$. Monophasic fever induced by 0.05 μg $\text{TNF}\alpha$ peaked at 60 min postinjection and the T_{br} stayed elevated thereafter throughout the entire recording period. The pyrogenic effects of the two highest doses were biphasic; an initial peak occurred at about 60 min postinjection and was followed by a second rise in T_{br} that persisted until the end of the recording period.

II. $\text{TNF}\beta$

$\text{TNF}\beta$ also elicited dose-dependent increases in T_{br} and NREMS. The three lowest doses tested induced slight increases in NREMS (Table 1) though only the increase in NREMS after the lowest dose was significant. The highest dose of $\text{TNF}\beta$ (0.2 μg) elicited a relatively robust increase in NREMS of about 15% across the 6 h experimental period. Only the highest dose affected REMS; $\text{TNF}\beta$ induced a slight but significant decrease in REMS across the 6 h. Although there were statistically significant correlations found between the hyperthermic and hypnogenic effects of $\text{TNF}\beta$, the changes in NREMS in response to $\text{TNF}\beta$ did not parallel the febrile effects as clear as in the case of $\text{TNF}\alpha$. Though the lowest dose of $\text{TNF}\beta$ (0.0005 μg) enhanced NREMS, it did not increase T_{br} .

The highest dose of TNF β (0.2 μ g) elicited a biphasic fever comparable to the effects of 0.5 μ g TNF α .

III. TNF α fragments

TNF α fragments 44-68, 46-65, 69-100, 101-135 and 140-157 failed to alter NREMS. One of these (TNF α ₄₄₋₆₈) did induce a reduction in REMS and caused a slight fever (Table 1). Another fragment TNF α ₆₉₋₁₀₀ also induced fevers but failed to alter the sleep parameters measured; this fragments elicited a dose-dependent increases in T_{br}. It is noteworthy that unlike the whole TNF α molecule, the effect of the fragment on the T_{br} was monophasic with a latency of 100-120 min (Fig. 4).

Two fragments with overlapping sequences (TNF α ₁₀₋₃₆ and TNF α ₃₁₋₆₈) were both pyrogenic and somnogenic. These fragments were virtually equipotent; the 5 μ g dose did not show any significant effect on T_{br} or sleep, but 25 μ g of both fragments elicited a monophasic fever with a maximum amplitude of about 1-1.2 °C paralleled with a significantly increased NREMS across the 6 h recording period. A statistically significant correlation was found between the thermoregulatory and NREMS responses to these fragments. The pyrogenic effects of these fragments resembled the second phase of the TNF α -induced fever although the amplitudes of changes were much lower even after the injection of doses as high as 25 μ g. The fragment TNF α ₃₁₋₄₅ increased NREMS but failed to significantly affect T_{br}. The fragment TNF α ₁₀₋₆₉ also increased NREMS and reduced REMS after the injection of 10 and 5 μ g doses, respectively.

IV. FMLP

One facet of TNF α activity is its chemotactic activity for neutrophils and monocytes. Previously, it was suggested that this activity could be due to contaminating amounts of N-formylated methionyl peptides. Therefore, we determined whether FMLP was somnogenic. After doses of 10 pmol or 100 pmol were given ICV, sleep and T_{br} remained close to normal values.

Experiment No. 2

The injection of 1-2 mg pseudomurein per rabbit did not result in significant effects on SWS, REMS, or EEG delta wave voltages (Table 2) nor did it affect T_{br} or colonic temperature (T_{co}) (data not shown). The injection of 4 mg pseudomurein per rabbit increased SWS significantly over the six hour recording period (Table 2). The differences in SWS occurred during the first 4 hours of the experiment; no differences were observed in hours five and six (Fig. 1 A). A similar time course in enhanced EEG δ wave voltage was observed (Fig. 1) and these increases were significant across the 6 hour recording period (Table 2). REMS was not affected by this dose of pseudomurein (Table 2, Fig. 1 B). While T_{co} s measured at the end of the six hour recording period were not effected by injection of pseudomurein, T_{br} s recorded at 10 min intervals revealed that a transient increase in T_{br} occurred, peaking during the second postinjection hour (Fig. 1, D).

To evaluate the possibility that endotoxin contamination might have contributed to the observed sleep effects, the LAL test was used to estimate, and polymyxin B sulfate was used to inactivate, any possible endotoxin contamination: A suspension of 1 mg/ml pseudomurein in PFS

contained a LAL reactivity of between 1.25 ng/ml and 12.5 ng/ml CSE. A concentration of 0.01 mg/ml Polymyxin B sulfate was sufficient to inactivate 10 ng/ml of CSE in the LAL assay. Interestingly, 1 mg/ml of Polymyxin B sulfate was needed to inactivate the LAL activity of 1 mg/ml pseudomurein. Since a much higher dose of Polymyxin B was needed to inactivate the pseudomurein LAL activity than needed to activate CSE activity, this suggests that the pseudomurein itself had LAL activity.

When pseudomurein was preincubated with 1 mg/ml Polymyxin B sulfate prior to injection (4 animals with 2 mg, 4 animals with 4.5 mg pseudomurein), the observed effects were similar, although less pronounced, to those obtained after injection of pseudomurein not pretreated with Polymyxin B. SWS and δ -wave voltages were significantly increased and a slight nonsignificant enhancement of REMS was observed (Table 2). T_{CO} s measured at the end of the recording period were not affected (data not shown). A transient increase in T_{Br} occurred during the second postinjection hour and was of equal magnitude, shape, and timing as the increase observed after injection of pseudomurein that was not pretreated with polymyxin B (data not shown).

To investigate whether the observed pseudomurein effects on sleep parameters and T_{Br} were due to the particulate or to the chemical nature of the sample, polystyrene microspheres were injected via the same route and in comparable concentration. (5×10^9 sacculi are contained in 4.5 mg of a cell wall preparation of *Staphylococcus aureus* that was prepared in the same way as the pseudomurein [79]). The injection of 5×10^9 microspheres in 1 ml PFS had no effects on sleep parameters (Table 2), or on T_{CO} or T_{Br} (data not shown).

Experiment No. 3

PGE₂ induced dose-dependent increases in T_{br} (Fig. 2) thereby confirming previous observations (44, 131). The increase in T_{br} began within minutes of the ICV injections and then peaked about one hour later. The lowest dose of PGE₂, (0.25 nmol), induced about a 0.5° rise in T_{br}. The response after this dose lasted about one hour. The highest dose of PGE₂, 10 nmol, induced a maximum increase of about a 1.5° increase in T_{br} and the duration of the hyperthermic response lasted about 2.5 hour. Within three hours of injection, T_{br}s were close to control values.

The effects of PGE₂ on sleep/wake cycles were not as obvious as its effects on T_{br}. None of the doses of PGE₂ tested altered duration of either NREMS or REMS across the six hour recording period (Table 3). However, if the analyses were confined to the first hour after injection, PGE₂ induced significant dose-dependent biphasic effects on NREMS (Fig. 3). During the first twenty four min after injection, NREMS was decreased relative to corresponding control values. In contrast, during the last 24 min of the first postinjection hour, duration of NREMS was significantly elevated above control values. PGE₂ also altered REMS. After injection of the 2.5 or 10 nmol PGE₂ dose, but not after the 0.25 or 5 nmol dose, REMS was inhibited during the last 36 min of the first postinjection hour. However, the control REMS values of the rabbits used for assaying the 5 nmol dose were very low, thus rendering it difficult to distinguish an inhibitory response to this dose of PGE₂. After the first postinjection hour, there were no significant effects of PGE₂ on sleep. Although PGE₂-induced behavioral effects were not sys-

tematically quantified, at the doses tested PGE₂ did not induce any gross behavioral abnormalities.

PGD₂ failed to induce significant changes in T_{br} after ICV injection of the six lowest doses tested. However, after the highest dose of PGD₂, 500 nmol, there was an increase in T_{br} of about 0.5° which began about forty min after injection then persisted for about two hours (data not shown). PGD₂ also failed to affect either NREMS or REMS across the six hour recording period (Table 4). In addition, if the analyses were confined to the first postinjection hour as done for PGE₂, no dose of PGD₂ tested significantly altered either NREMS or REMS (e.g., Fig. 4). As described above for PGE₂, PGD₂ did not appear to induce abnormal behavior at the doses tested although this was not systematically documented.

Experiment No. 4

a) Effects of ip injections of CCK

Ten µg/kg CCK IP significantly decreased W and 40 µg/kg CCK significantly increased NREMS in the first postinjection h (Figure 5), the time period within which CCK affects rat sleep (87). The sleep-wake activity returned to the baseline level by the second postinjection h, and there were not significant changes found in the sleep-wake activity across the 6-h period (ANOVA, $p > 0.05$). After the injection of 2.5 µg/kg CCK there was a nonsignificant increase in sleep in the first postinjection h. Thereafter, NREMS was suppressed in the remainder of the experimental period (Figure 5) [2.5 µg/kg CCK, ip: ANOVA for NREMS: drug effect: $F(1,6)=4.2$ $p < 0.05$, time effect: $F(5,6)=1.5$, interaction: $F(5,6)=1.5$; ANOVA for REMS: drug effect: $F(1,6)=0.3$, time effect:

$F(5,6)=0.1$, interaction $F(5,6)=0.3$; ANOVA for W: drug effect: $F(1,6)=4.6$ $p<0.05$, time effect: $F(5,6)=2.2$, interaction: $F(5,6)=1.5$]. None of the tested doses of CCK affected the maximal EEG delta wave amplitudes during NREMS in the first postinjection h (Table 5).

The somnogenic effects of CCK were accompanied by dose-dependent decreases in T_{br} . While 2.5 $\mu\text{g/kg}$ CCK did not affect T_{br} , 10 $\mu\text{g/kg}$ CCK slightly decreased T_{br} for about two h, and 40 $\mu\text{g/kg}$ CCK elicited a significant hypothermia for about three h. (Figure 5) [ANOVA for 40 $\mu\text{g/kg}$ CCK: drug effect: $F(1,18)=15.8$ $p<0.05$, time effect: $F(17,18)=0.2$, interaction: $F(17,18)=0.2$].

b) Effects of ICV injections of CCK

In contrast to the effects of IP injections, ICV injections of CCK did not cause any significant increase in NREMS. Rather, 0.05 μg CCK reduced REMS across 6 h [ANOVA, drug effect: $F(1,6)=4.2$ $p<0.05$, time effect: $F(5,6)=1.6$, interaction: $F(5,6)=0.2$] and 0.5 μg CCK slightly, but statistically significantly decreased NREMS during the first postinjection h (Figure 6). The highest dose of CCK (2 μg ICV) did not cause significant changes in any of the measured sleep parameters. The maximal EEG delta wave amplitudes were not affected by any doses of CCK (Table 5).

Injections of 0.05 μg and 2 μg , but not 0.5 μg CCK, elicited statistically significant decreases in T_{br} for about one h, although the amplitudes of these changes were minor (Figure 6) [ANOVA for 0.05 μg CCK: drug effect: $F(1,18)=7.1$ $p<0.05$, time effect: $F(17,18)=0.2$, interaction: $F(17,18)=0.2$; and for 2 μg CCK: drug effect: $F(1,18)=4.7$ $p<0.05$, time effect: $F(17,18)=1.6$, interaction: $F(17,18)=0.7$]].

Experiment No. 5Cell culture and immunofluorescence staining

All cell lines grew well after subculture; the three glioblastoma cell lines stained positive for GFAP, and neuroblastoma cells stained positive for neurofilament. Neuroblastoma cells reach confluence as determined by cell number at 7 days (data not shown). Growth curves of each glioblastoma cell line were also developed (Fig. 7); all cell cultures reached confluence in 5-7 days in the 96-well plates. There also was a correlation between the number of cells per cm^2 and mg protein in wells (Fig. 7)

IFN γ -induction of HLA D_R antigen

Of the three glioblastoma cell lines, HTB14 moderately expressed HLA D_R antigen prior to rhIFN γ treatment (Fig. 8), thus confirming a previous result (73) that some glioblastoma cell lines spontaneously express HLA D_R . Glioblastoma cell lines HTB16 and HTB17, and neuroblastoma cell line HTB11 were all HLA D_R negative before treated with rhIFN γ (Fig. 8). The effect of rhIFN was dose dependent from the dose 10 to 5×10^3 U/ml for all three glioblastoma cell lines, and reached a plateau at a dose of 100 U/ml for HTB14, and 1000 U/ml for HTB16 and HTB17 (Fig. 8). IFN γ failed to induce HLA D_R in the neuroblastoma cell line. The effect of IFN γ on HLA D_R over time was determined in HTB16 cells. After the treatment with 1000 U/ml of rhIFN γ for 48 hrs, HLA D_R antigen was detectable on HTB16 cells. This inducing effect reached a peak on the fifth day (Fig. 9). On day 5, IFN γ was removed from the culture medium and HLA D_R expression was still detectable two days later.

Effects of TNF α , TGF β 1 and TGF β 2 on IFN γ -induced HLA DR expression

Consistent with other reports (9, 120), rhTNF α alone was unable to induce HLA DR expression on HTB16 cells. However, when simultaneously added with rhIFN γ (100 U/ml or 500 U/ml), hrTNF α amplified the induction of HLA DR by rhIFN γ in a dose-dependent manner. Enhanced HLA DR expression was detectable at the lowest concentration of rhTNF α (0.1 ng/ml) used in the experiments; optimal effects were obtained by incubating cells with rhTNF α at 50 ng/ml and rhIFN γ at 100 U/ml for 4 days (Fig. 10A). The specificity of this synergistic effect of TNF α was confirmed using neutralizing antibodies against TNF α . The antibody at the concentration of 10 μ g/ml almost completely blocked the effect of TNF α (Fig. 10B).

The potentiation of IFN γ -induced HLA DR expression by TNF α in HTB16 cell line was evident only 24 hours after incubation began (Fig. 11A). Thus, rhTNF α not only amplified the effect of rhIFN γ , but also induced a more rapid HLA DR expression. This synergistic effect of TNF α reached its peak on the fourth day and then persisted to the eighth day of the study (Fig. 11A).

TGF β 1 and β 2 both reduced IFN γ -induced HLA DR expression. The lowest concentrations of both types of TGF β used (0.01 ng/ml) were sufficient to produce a marked inhibitory effect; TGF β 1 at 1 ng/ml and TGF β 2 at 10 ng/ml generated maximal effects (Figs. 12A & 13A). If a higher concentration of rhIFN γ (1000 U/ml) was used, the inhibitory effects of both TGF β 1 and β 2 were not observed (data not shown). The inhibitory effects of TGF β 1 and β 2 on IFN γ -induced HLA DR -expression was reversed if neutralizing antibodies against TGF β 1 or β 2 were added to the culture medium (Figs. 12B & 13B). It was important to combine rhIFN γ , TGF β 2,

and respective antibodies at appropriate concentrations to obtain ideal blocking effects of antibodies. For example, the effects of anti-TGF β 2 antibodies were dose-dependent at concentrations ranging from 1-25 μ g/ml when the dose of rhIFN γ was 100 U/ml or 500 U/ml and the dose of TGF β 2 was 1 ng/ml (Fig. 13B). Using a higher dose of TGF β 2 (10 ng/ml), only the highest dose (25 μ g/ml) of the anti-TGF β 2 antibody could block the effect of TGF β 2 (Fig. 13B).

The effects of TGF β 1 and β 2 on IFN γ -induced HLA β 2R expression over time were also determined. The inhibitory effects of TGF β 1 and β 2 on IFN γ -induced HLA β 2R expression were first observed on day 5 of incubation. The maximal effects were observed after 7 days of treatment (Fig. 11B).

IL-1 β and PGE $_2$ impaired IFN γ -induced HLA β 2R expression

In agreement with data obtained using brain endothelial cells (120), hrIL-1 β induced a dose-dependent decrease of IFN γ -induced HLA β 2R in HTB16 cells (Fig. 14A). The effect of IL-1 β resembled, but was not as potent as, that of TGF β . Since IL-1 and PGE $_2$ reciprocally affect each others production in some cell types (109), and PGE $_2$ inhibits Ia expression on macrophages (166), the effect of PGE $_2$ on HLA β 2R expression was also examined. A dose-dependent suppression of IFN γ -induced HLA β 2R expression by PGE $_2$ was observed after 4 days of incubation (Fig. 14B).

Experiment 3 - Failure of IFN α , 5-HT, PGD $_2$, VIP, DSIP, MDP and hydrocortisone to regulate HLA β 2R expression

Several additional substances were tested alone and in combination with IFN γ to determine their effects on HLA β 2R expression. These sub-

stances (IFN α , 5-HT, VIP, DSIP, MDP and hydrocortisone) failed to affect HLA β expression or IFN γ -induced HLA β expression in HTB16 cells (Table 6).

DISCUSSION

Experiment No. 1

During infectious disease NREMS is enhanced (174, 175). This central nervous system response to infection seems to be mediated via the ability of specific bacterial (99, 101, 105) or viral (119) products to enhance cytokine production (reviewed 105, 106). Previously, studies of the somnogenic actions of cytokines were focused on IL1; both IL1 α and IL1 β , as well as a fragment of IL1 β , IL1 β 208-240, enhance NREMS (106, 139) (see June 1, 1990 annual report). IL1s are part of a larger complex cytokine network which includes TNF α (also called cachectin) and TNF β (also called lymphotoxin). There are many regulatory relationships between IL1s and TNFs, as well as other cytokines, but these relationships in brain are very poorly understood. For example, TNF induces IL1 and TNF production but whether this occurs in brain is not known. Nevertheless, TNF α mRNA is in brain, glia produce TNF (43), and there are neurons that contain TNF α -like immunoreactivity (13). Systemic production of TNF is enhanced during and after sleep deprivation whereas, other forms of stress are less effective in altering TNF production (192). Previously, the somnogenic activities of TNF α were described (164). Both TNF α and TNF β interact with the same receptors and though they are distinct molecules, they often have similar biological activi-

ties (3). However, if TNF receptors are solubilized, TNF α but not TNF β binds to them. Furthermore, in some instances TNF α and β have distinct biological activities. For example, TNF α and β have opposite effects on the sympathetic nervous system (67). We thought it important, therefore, to investigate more thoroughly the somnogenic properties of TNF and to determine if TNF somnogenic activity could be localized to part of the TNF molecule. Both TNF α and β are somnogenic and that several TNF α fragments in the region of amino acid residues 10-69 are somnogenic. Other TNF α fragments, though possessing other TNF activities, were not somnogenic.

Experiment No. 2

The pseudomurein preparation used in this study increased the time animals spent in SWS, EEG δ -wave voltage, and caused a transient increase in T_{br} though REMS was not affected. These effects of pseudomurein on rabbit sleep and T_{br} are to our knowledge the first observations of CNS effects of this substance. Although only limited information is available on biological effects of pseudomurein, it was demonstrated earlier that in a rat arthritis model, pseudomurein-polysaccharide fragments purified from *Methanobacterium formicicum* were without effects after intraperitoneal injection; only intraarticular injection of high doses caused an acute inflammation (170). Also, pseudomurein was shown to be antigenic in animals and humans (22).

Previously, we have shown that cell wall preparations of *Staphylococcus aureus* or *Neisseria gonorrhoeae* injected IV in rabbits increased SWS, EEG δ -wave voltages, T_{co} , and T_{br} , and reduced REMS (79). About 4-5 times more pseudomurein was needed to obtain significant

effects as compared to staphylococcal cell wall preparations used earlier. In contrast to the staphylococcal and gonococcal cell wall preparations, pseudomurein did not decrease REMS and the onset of the increases in SWS and EEG δ -wave voltage were not delayed by one hour. After pseudomurein treatment, the increases in SWS and EEG δ -wave voltage were limited to the first 4 postinjection hours, this was similar to results obtained after injections the gonococcal peptidoglycan preparation. In contrast, after injection of staphylococcal cell walls, these effects persisted until the end of the 6 hour recording period. The increase in T_{br} , after pseudomurein injection, was rather transient while this effect was longer lasting after injection of eubacterial cell walls.

When staphylococci are phagocytized by murine bone marrow-derived macrophages, their cell walls can be partially digested (186), most probably by lysozyme. In the process of digestion, the macrophages produce and release into their medium low molecular weight cell wall fragments including muramyl peptides. Some of these fragments have somnogenic activity in rabbits (78). Also, the somnogenic actions of muramyl peptides are well known and several chemical structure - somnogenic activity relationships have been established (80, 99, 105). Importantly, if the muramic acid moiety of muramyl peptides contain an internal 1-6 anhydro structure, the substances are more potent than the corresponding hydrated compounds (102). When energy calculations are performed on the glycan strand of pseudomurein with talosaminuronic acid in 1C conformation, which represents the normal glucose chair conformation as it exists in muramic acid of murein, the resulting 3-dimensional structure of the sugar strand is dissimilar to that of the sugar strand

of murein (115) and, indeed, makes it very difficult to construct a net-like structure for pseudomurein. Instead, it was deducted from energy calculations that the 1C_4 conformation of talosaminuronic acid, the reversed chair conformation, results in a 3-dimensional structure of the glycan strand which resembles that of murein (116). Interestingly, this 1C_4 conformation is the one that must be assumed for the 1,6-anhydromuramic acid.

It seems inadequate at this time to propose degradation pathways by which pseudomurein exerts its somnogenic and pyrogenic effects: Pseudomurein is resistant to lysozyme (84), the key enzyme for the degradation of eubacterial peptidoglycan in macrophages. Also, the accumulation of unusual ϵ - and γ -bonds in pseudomurein may protect it against attack by proteases (84). However, some enzymatic degradation processes for pseudomurein have been described recently: An extracellular enzyme produced by a streptomycete from cow manure has the capability to lyse a pseudomurein-containing methanogen (14). Also, a peptidase, hydrolyzing the ϵ -ala-lys bond of pseudomurein, was purified from *Methanobacterium wolfei* (91). Whether such processes are involved in the biological response of pseudomurein remains undetermined.

Despite the similarities in the somnogenic and pyrogenic responses of rabbits to pseudomurein or eubacterial peptidoglycan, there are also differences. Most notably the failure of pseudomurein to decrease REMS. This suggests that IL-1 is not the mediator of the pseudomurein-induced sleep and temperature responses, as has been proposed for muramyl peptides, since IL-1 decreases REMS when injected IV in rabbits (164).

Although endotoxin is not a constitutional component of archaeobacteria, the pseudomurein sample used in the current experiments contained

some LAL assay reactivity. However, to inactivate this LAL reactivity a hundred-fold more Polymyxin B sulfate was needed than for the control standard endotoxin. This would point to contamination with an endotoxin that is very LAL reactive or very inaccessible to inactivation by polymyxin B or, more likely, that pseudomurein by itself has some LAL reactivity. It has been shown that the LAL assay is not specific for endotoxin and that eubacterial peptidoglycan contains LAL reactivity 3 to 5 orders of magnitude less potent than endotoxin (5, 187). Thus, the effects of pseudomurein in the LAL test might be considered a further aspect of biological activity of this substance, possibly due to the structural similarity to eubacterial peptidoglycan. Also, the sleep effects of endotoxin observed after IV administration are characterized by suppression of REMS and can be completely abolished by polymyxin B pre-treatment (104), unlike those observed here for pseudomurein.

The effects on sleep and temperature could be due to activation of macrophages or other mammalian cells which then release effector molecules like cytokines or digest pseudomurein into smaller components which might act similar to sleep inducing muramyl peptides, which can be tailored from eubacteria (78). Polystyrene microspheres of 1 mm diameter are phagocytized by macrophages *in vitro* (86). Also, microspheres of 3 mm diameter injected IV in beagle dogs are found consistently within phagocytizing cells; they eventually relocated in the liver and spleen where they remained indefinitely (85). The failure of a suspension of polystyrene microspheres of similar size and concentration to elicit any sleep and temperature effects in the assay systems used here excludes the possibility that any suspension of particles similarly

sized as bacteria is capable of eliciting the observed effects by activation of macrophages.

Experiment No. 3

The pyrogenic actions of PGE₂ reported here are consistent with those of previous studies. Thus, the time course of the fever responses and the doses of PGE₂ needed to elicit those responses are similar to those previously reported (e.g., 44, 131). The effects of PGE₂ on sleep are also similar to those reported by Ueno, et al. (179). In rats the bolus injection of PGE₂ into the preoptic anterior hypothalamus induced a transient biphasic sleep response similar to the results reported here. These relatively short PGE₂-induced sleep responses stand in contrast to the prolonged inhibition of rat sleep if PGE₂ is continuously infused into the third ventricle (126). Such differences may be due to PGE₂ instability *in vivo*, thus with continuous infusion of PGE₂, the initial inhibitory effects observed with bolus injections of PGE₂ may persist. However, it is noted that other putative sleep factors also have short half lives, e.g., IL-1 in blood has a half life of about 10 min, yet are capable of eliciting prolonged changes in sleep (98). The inhibitory actions of PGE₂ on sleep are consistent with the report that an antagonist of PGE₂ (AH6809) (126) enhances sleep. However, it is more difficult to interpret the reports suggesting that inhibitors of PG synthesis (e.g. indomethacin and diclofenac) inhibit sleep (71, 133). Finally, while PGE₂ seems to increase wakefulness in both rats and rabbits, PGE₂ decreases vigilance and motor activity in cats (72), indicating species differences in its effects.

The results reported herein using PGD₂ are also consistent with the literature to the extent that the high dose of PGD₂ induced a hyperthermia (51, 52). However, the almost complete lack of effects of PGD₂ on rabbit sleep seem to differ from the somnogenic actions of PGD₂ previously reported for cats (112), rats (178) and monkeys (140). In fact, in rabbits, the highest dose of PGD₂ used inhibited sleep for about one hour instead of promoting sleep. The reasons for these differences are unknown though there are some plausible explanations. Similarly, as for PGE₂, there are likely species differences in responses to PGD₂. Alternatively, the lack of a somnogenic action of PGD₂ may be due to the time of day it was injected. Inoué and colleagues (76) reported that in rats, PGD₂ and other putative sleep factors had little effect on sleep if given during daylight hours when rats normally sleep near maximum values. However, circadian variations in sleep duration are small in the rabbit, and a great variety of sleep promoting substances have been found effective when injected during the light cycle (163).

The current results obtained using PGD₂ fail, in part, to replicate a previous preliminary report by one of us (100). However, in that study, only one somnogenic dose was found and only four animals were tested. Further, at the time of that work, we were unaware of the sleep-promoting actions of endotoxin (101), which is a common contaminant of many reagents. The sample tested was a gift and was not shown to contain immune-reactive PGD₂ as was done for the current study nor was an assessment of endotoxin contamination made. Regardless of those preliminary studies, current results indicate that over a very wide dose range, PGD₂ lacks somnogenic activity in rabbits.

The clearest difference between the present study and those of Hayaishi and colleagues is methodological in that the latter group usually used a continuous infusion of PGs into the third cerebral ventricle, whereas in the current study, PGs were injected as a bolus into a lateral ventricle. This difference could lead to the differences in results obtained, particularly, as mentioned above, for the duration of the waking actions of PGE₂. This suggests that if PGs are involved in sleep-wake regulation then their production (and effects) are probably dependent upon the continuous stimulation of arachidonic acid metabolism by another substance (sleep factor). Indeed, several putative sleep factors have the capacity to enhance PG production (e.g., IL-1 [35, 98], IFN α_2 [103], and growth hormone releasing hormone [44, 138]). However, whether the sleep-inducing actions of these substances are dependent upon enhanced PG production is unknown, although the somnogenic actions of muramyl dipeptide persist in rabbits treated with the cyclooxygenase inhibitor acetaminophen (96). It is also noted that other substances that enhance PG production, e.g., interleukin-6, and induce fever, do not affect sleep (142).

Experiment No. 4

The effects of CCK on sleep-wake activity of rats are well documented (30, 87, 121, 151). Although preliminary attempts to demonstrate somnogenic activity of CCK have been done in cats (42), our present work represents the first systematic description of the effects of exogenously administered CCK on normal sleep in a second species.

We report here that 10 μ g/kg CCK decreases W, and 40 μ g/kg CCK selectively increases NREMS and elicits hypothermia in rabbits. In con-

trast, ICV injections of CCK or IP injection of 2.5 $\mu\text{g/kg}$ CCK did not induce NREMS in rabbits, in fact, after 0.05 μg ICV and 2.5 $\mu\text{g/kg}$ IP CCK NREMS was decreased and after 0.05 μg CCK REMS was reduced, although these effects were very small. The results are similar to those obtained in rats where increases in NREMS (87) and decreases in temperature (87, 88, 193) were also found after IP administration of CCK, furthermore ICV bolus injection (155) or chronic ICV infusion of CCK (29) failed to promote sleep. The dose-range for the hypnogenic effects of CCK is similar in both species. A threshold dose of 10 $\mu\text{g/kg}$ CCK in rats was reported (87), others also observed sleep increases after 10 $\mu\text{g/kg}$ CCK (151), and in a third study 16, but not 8, $\mu\text{g/kg}$ CCK promoted NREMS (30). IP injection of 4 $\mu\text{g/kg}$ (87) or 2 $\mu\text{g/kg}$ (155) CCK were ineffective on sleep of rats.

The enhanced sleep after CCK treatment was not accompanied with changes in EEG delta wave amplitudes. In contrast, recovery sleep following sleep deprivation (146), the sleep that accompanies acute infections (174, 175) and the sleep elicited by several sleep-promoting substances such as IL-1 (98), MDP (96) or growth hormone-releasing hormone (138) are characterized by increased EEG delta wave amplitudes during NREMS. This suggests that the underlying mechanisms of CCK-induced sleep and sleep induced by the above mentioned interventions may be partially independent.

The dose-dependent hypothermic effects of systemically injected CCK are similar to those reported in rats (87, 88). These thermoregulatory effects parallel the hypnogenic effects of CCK. ICV administration of 0.05 and 2 μg CCK also elicited a statistically significant decline in T_{br} . The magnitude of these changes, however, were so minor that the

physiological significance of these responses seems questionable. Similarly, Lipton and Glyn reported that ICV injection of 5 μ g CCK does not alter the body temperature in rabbits (117).

The mechanisms mediating the effects of exogenous CCK on sleep-wake activity are not known. Since the peripheral-circulating and the central-neuronal CCK pools are separated by the blood-brain barrier, which is practically impermeable to CCK (147), we assume that systemic injection of CCK mainly mimics the effects of the endogenous, peripherally circulating hormone, whereas ICV administration of CCK mimics the effects of the neurotransmitter/neuromodulator CCK. Since no somnogenic effects were observed after central injection of CCK it seems that the site of hypnogenic action of CCK is peripheral. It is known that sensory inputs conveyed by the n. vagus contribute to the regulation of sleep-wake activity (153). It has also been reported that several effects of CCK are mediated by the n. vagus (23, 47, 165, 182). It is possible, therefore, that the somnogenic effects of CCK are also mediated by n. vagus. Another possibility is that CCK causes the release of other sleep-promoting substance(s) from the periphery. The role of insulin seemed likely, since insulin elicits sleep in rats (26, 158), and CCK is a potent stimulator of insulin release (e.g., 149, 180). Experiments in rats indicate, however, that insulin plays little if any role in the hypnogenic effects of CCK (Kapás et al, submitted).

It is possible that the somnogenic doses of CCK are not physiological although it is difficult to know since the concentration of CCK at the hypnogenic site, when its secretion is physiologically stimulated (e.g., after eating), is unknown. It is likely that when CCK is released within the small intestine it reaches high concentrations in circum-

scribed areas. To achieve such high concentrations experimentally, systemic injections of relatively large amounts of the peptide are needed. Regardless of the specific mechanism by which CCK affects sleep and thermoregulation, current results clearly show that the hypnogenic effects of CCK are not species specific. Furthermore, CCK enhances sleep in a species, in which it also suppresses food intake. It supports the idea that the sleep-promoting and food intake reducing effects are closely associated, presumably different manifestations of satiety. Finally, the experience of postprandial sleepiness, when the secretion of CCK is physiologically stimulated, further suggests that one of the primary actions of peripherally released CCK may be sleep promotion.

Experiment No. 5

Regulation of Class II MHC expression on astrocytes was investigated because of its association with CNS pathogenesis of autoimmune diseases, such as narcolepsy, and its importance in the initiation of immune responses during infection within the CNS. Transformed human CNS cell lines were used as a model *in vitro* system to examine the ability of some substances to alter HLA_{DR} expression (150, 195). Our results confirmed those of others in that IFN γ stimulated glial cells to express HLA_{DR} *in vitro*. The CNS was previously thought to be an immune privileged site because of the blood-brain barrier and its lack of lymphatic drainage. It is now recognized that, similar to peripheral systems, the immune response in the CNS requires the presence of several cytokines, antigen-presenting cells, and lymphocytes. Furthermore, activated T lymphocytes enter into the rat brain without major histocompatibility complex (MHC) restriction and antigen specificity, supporting the con-

cept that the CNS is actively involved in immune reactions (66). These T lymphocytes could serve as a source of IFN γ . However, Traugott and Lebon (176) report HLA Δ R antigen and IFN γ are both present on astrocytes at the edge of active multiple sclerosis lesions and in the adjacent area, suggesting astrocytes may also have the ability to synthesize IFN γ , which could be responsible for local induction of Ia antigen expression.

In our preliminary study, HLA Δ R expression in glioblastoma cells (HTB14) was also examined using immunofluorescence staining techniques. Visibly, the intensity of the staining seemed stronger, and a greater number of cells were positively stained if cultures contained IFN γ . However, this method for determining HLA Δ R expression was not sufficiently quantitative for our purposes. Therefore, we then established an ELISA to quantify HLA Δ R expression on the cell surface. Furthermore, the amount of protein in each cell was quantified, thus allowing HLA Δ R to be expressed as absorbance per mg protein. This is important because the hyperplastic and/or hypertrophic actions of cytokines *in vitro* are relatively uninvestigated. Thus, using the ELISA and protein assay, OD values are adjusted without the necessity of determining the reason for the increase or decrease of HLA Δ R expression (due to stronger or weaker expression of HLA Δ R per cell or changes in the number of cells expressing HLA Δ R). Another advantage of using a protein assay is that determining protein amount is more rapid and accurate than counting cell numbers.

There are conflicting reports on the effects of TNF α on MHCII (also called Ia in mouse and rat) expression in systemic cells. TNF α was reported to induce Ia antigen and potentiate IFN γ -induced Ia antigen in

a murine macrophage cell line (17), and pancreatic cells (189), but it suppressed IFN γ -induced Ia expression on murine peritoneal macrophages (128). In human umbilical endothelial cell cultures the effects of TNF α on IFN γ -induced MHCII expression were dependent upon the order that cells were exposed to TNF α and IFN γ (113). TNF α enhanced IFN γ -induced MHCII expression when added twenty-four hours after IFN γ treatment, whereas TNF α inhibits IFN γ -induced MHCII expression when added simultaneously with, or before, IFN γ . Data presented here suggest that TNF α alone does not directly alter HLA α _{DR} expression, but markedly elevates the rate and extent of IFN γ -induced HLA α _{DR} expression in human glial cells. This synergistic effect of TNF α also occurs in rat astrocytes and brain endothelial cells (9, 120). TNF α is produced *in vitro* by astrocytes and microglia cells, (21, 159) and is secreted by fetal mice brain cells (191), thus suggesting that this cytokine is present in the brain. The mechanism for the TNF α -IFN γ synergistic effect on MHCII expression is not known; however, one possible mechanism may involve IFN γ up-regulation of TNF α receptor expression (9).

The effects of TGF β 1 and TGF β 2 are equivalent in most *in vitro* biological assay systems (20). Both TGF β 1 and β 2 antagonize Ia expression in astrocytes (160, 195). In agreement with these results, our evidence indicates that TGF β 1 and β 2 decrease IFN γ -induced HLA α _{DR} in the human glioblastoma cell line HTB16. We also used neutralizing anti-TGF β 2 antibody to examine whether endogenous TGF β 2 was present in our culture system. The antibody inhibited the effect of porcine TGF β 2 but did not influence HLA α _{DR} expression when cells were incubated with the antibody alone or with the antibody and IFN γ (data not shown here). We demonstrated that the antibody was effective with exogenous porcine TGF β 2 but

did not determine if it was able to cross react with human glioblastoma-derived TGF β 2 probably present in supernatants of HTB16 cell cultures. However, there is evidence that TGF β 2 is (immunologically) identical to glioblastoma-derived T cell suppressor factor. Therefore, TGF β 2 activity may not exist in our HTB16 glioblastoma cell line cultures. In contrast to the effects of TNF α , which enhanced IFN γ -induced MHCII within 24 hours, TGF β required more than 5 days of incubation before its effect became manifest. These different time courses of effects may be important in the regulation of the immune response *in vivo*. Thus, the sequences of the actions of cytokines and/or cytokine-cytokine interactions on the expression of MHCII might be crucial in the initiation and development and termination of the immune response in brain.

Previous studies dealing with the relationships between IL-1 and Ia expression were focused on the association of positive Ia expression with the production of IL-1 (48, 56, 184), because the activation of T cells requires the following signals from APC: antigen, Ia molecules, IL-1, and recently noticed, intercellular adhesion molecules (ICAM) (54). Although the effects of IL-1 on Ia expression have not been addressed adequately, IL-1 α and β inhibit IFN γ -induced Ia expression in rat synovial fibroblasts and brain endothelia (81, 120). In current studies, the inhibitory effects of IL-1 β on HLA D_R expression in glioblastoma cells were not as potent as these of TGF β or PGE $_2$, suggesting IL-1 β may play a moderate, but not a key, role in regulating class II MHC expression in glial cells.

The importance of PGE $_2$ in mediating inflammation and immune responses has been extensively studied (108, 168). PGE $_2$ inhibits IFN γ -induced Ia expression in macrophages (166), and is involved in a feed-

back loop mediating the inflammatory response. PGE₂ causes a dose-dependent decrease of IL-1 production by lipopolysaccharide-stimulated macrophages, and addition of IL-1 to macrophage cultures results in an increase of PGE₂ level in supernatant (109). In the CNS, almost all cell types produce PGs, though the patterns of PG release of different cell types may vary (90) and PGs have many biological actions in the brain. Current findings suggest the possibility that locally present PGE₂ inhibits HLA_{DR}/Ia expression on glial cells and thus may play an important role in immune reaction within the CNS.

Unlike PGE₂, PGD₂ does not affect HLA_{DR} expression in glioblastoma cells indicating it is not involved in MHCII regulation. The other substances tested in this study also failed to modulate HLA_{DR} expression either alone or in combination with IFN γ . Although IFN α inhibits MHCII expression in systemic cells and in cells of the CNS, we could not replicate those results. The biological activity of our TNF α was verified in an anti-virus assay. Our data obtained with VIP, another recognized immunomodulator within the CNS (136), also are not in agreement with earlier results (53) which indicates that VIP could attenuate IFN γ -induced Ia expression on astrocytes derived from newborn rats. Besides the possible species specificity, there may be differences between cells of adults and newborns. There may also be differences in responsiveness of malignant cell lines from that of primary cells cultures to VIP. DSIP is another neuropeptide included in this study because it is found both within the brain and in immune cells (60). It also failed to affect HLA_{DR} expression in HTB16 cells.

Within the concentrations ranges used in this study (10^{-8} to 10^{-5} M), 5-HT failed to suppress IFN γ -induced HLA_{DR} expression in glioblas-

toma cells. In contrast, 5-HT was reported to alter Ia expression in murine macrophages (169). This may indicate the possibility that 5-HT is not involved in counteracting the stimulatory effect of IFN γ on MHCII expression in astrocytes, or the cell line we used lacks receptors for 5-HT.

It is well known that glucocorticoids have profound immunosuppressive effects and they are used clinically in many inflammatory and autoimmune diseases, although the precise mechanisms of their actions are still unclear. There is no consensus in the literature on the effect of glucocorticoids on MHCII expression (55, 185). It was, therefore, not surprising that hydrocortisone did not affect HLA D_R expression in the glial cell lines used in this study.

Massa and ter Meulen (124) suggested the bacterial cell wall component MDP as a possible candidate for MHCII induction in the CNS. However, we were unable to replicate in our human glioblastoma cells their result on MDP-induced Ia expression in rat astrocytes. It is noted here that MDP also failed to induce Ia expression in rat macrophages (124). The reasons for these failures of MDP to induce HLA D_R are unknown.

Regardless of whether bacterial products or certain neuropeptides alter MHCII expression, it is currently clear that many substances known to be brain products, *i.e.*, IFN α , TGF β , IL-1 β , TNF α and PGE $_2$, do modulate MHCII expression. It is thus likely that MHCII expression is regulated by locally present endogenous products within the CNS and that positive and negative feedback loops for this regulation exist. Our results further strengthen the concept that MHCII antigen plays a crucial role in initiating the immune response in the CNS. IFN γ and TNF α

may serve a major role in the development of immune response in the CNS, while TGF β , PGE₂ and IL-1 β may be involved in local immunosuppression.

GENERAL DISCUSSION

Criteria for Sleep Factors

Four fundamental experimental paradigms have been used to identify SFs. The first two are based on the hypothesis that some substances (SFs) are increased in concentrations during prolonged wakefulness or during infectious disease (reviewed, 12). As already mentioned, Legendre and Pieron (114) were the first to experimentally address this hypothesis using sleep deprivation. Several SFs have been identified using such paradigms; the list includes oxidized glutathione (GSSG), muramyl peptides and IL-1. A third approach was to isolate substances that are released during sleep. These substances might be responsible for the mediation of at least certain aspects of physiological sleep. This approach has resulted in the discovery of DSIP. A fourth method used to identify SFs was to assay substances for sleep-promoting activity known to be involved in the biological regulation of another substance known to be linked to sleep/wake cycles. Perhaps the best known SF identified in this manner is growth hormone releasing hormone (GRF); it was investigated because NREMS onset is associated with growth hormone (GH) release. To date, a variety of substances have been shown to alter sleep (Table 7); the list includes about 30 substances, many of which are well known for their other biological activities. Regardless of the experimental paradigm under which a SF was isolated or of its

other biological activities, it is generally agreed that in order for a substance to be classified as a SF it should induce physiological sleep. However, in practice, this criterion is not possible to test directly because animal models are used in which either excess sleep is induced or in which sleep is restored after some manipulation reduces it. Despite these experimental limitations, physiological-like sleep can often be recognized (Table 8) and several SFs appear to induce/enhance normal sleep. Several additional criteria for SFs have been proposed (reviewed, 11, 83) though often these are based on preconceived ideas of sleep rather than our knowledge of sleep regulation (106). Nevertheless, there are a few obvious criteria for SFs (Table 9). There are several putative SFs that meet these requirements; these include cytokines, the GRF/GH/somatostatin (SRIF), and the vasoactive intestinal peptide/peptide histidine isoleucine/prolactin (VIP/PHI/PRL) systems.

An Integrative Model for SFs

Historically, it has been a postulate within sleep research that the "true" SF would have biological actions specific to sleep and would act on the CNS executive sleep centers, which were also assumed to be primarily concerned with sleep regulation. However, there is much evidence strongly implicating at least three sets of compounds, cytokines, the GRF/GH/SRIF system and the VIP/PHI/PRL system, each of which have other biological actions, in physiological sleep regulation. Furthermore, a single center in brain necessary for sleep has not been demonstrated. It is possible, however, that multiple SFs, which are not specific for sleep, can elicit a specific sleep response if they operate in concert with each other (106). The SFs shown in Fig. 15 have been

shown in a variety of *in vivo* and *in vitro* systems to interact; they may enhance or inhibit the production or actions of one another. In this model, SFs are regulated through cascades of biochemical events though several of the pathways can also work in relative independence. Further, many feedback loops are involved; several of these are illustrated in Fig. 15 although additional aspects of regulation, e.g., the role of endogenous receptor antagonists are not illustrated. At present, we do not know the relative contributions of the individual substances to physiological regulation. However, it is emphasized that we think that the evidence for the central involvement of some of these compounds in sleep regulation, i.e., IL1, GRF, and VIP, is far greater than that for the other substances mentioned. Finally, the biochemical interactions shown were derived from experiments in which sleep was not monitored, thus the role that these interactions in sleep regulation needs to be evaluated.

The multiplicity of SFs, the numerous sleep-promoting pathways, which often act in parallel, and the many feedback loops provide a high degree of stability to sleep. Thus, changes in a single SF are not likely to alter sleep greatly, though the degree of change is likely to be dependent upon the relative importance to sleep of the specific SF. For example, blocking IL1 actions with the IL1 receptor antagonist (144, 145) or GRF actions with an anti-GRF antibody (Obál, et. al., unpublished) each reduce NREMS by about 25% thus indicating their importance. In contrast, cyclooxygenase inhibitors, which inhibit prostaglandin production, have little net effect on sleep. All the experimental conditions that reliably produce increases in sleep, i.e., prolonged sleep deprivation, infectious disease, excessive exercise, and

prolonged starvation, are pathologic. In these cases, multiple sites of actions and SFs are likely to be involved. For example, almost all of the substances mentioned in Fig. 15 are altered by infection. After less aggressive sleep-promoting experimental paradigms (e.g., increase in ambient temperature) the occurrence of sleep is statistical rather than an obligate phenomenon.

The putative SFs mentioned in Table 7 have biological activities in addition to altering sleep; some of these are not associated with normal sleep. For example, IL1 and certain PGs are pyrogenic, whereas entry into NREMS is usually associated with a decrease in T_{br} . The scheme in Fig. 16 illustrates how it is conceptually possible for substances that are not specific to sleep in their actions to elicit a specific sleep response. In this model, it is envisioned that a single SF will interact with more than one neuronal set. Each neuronal set will be involved in the regulation of two or more physiological parameters. Finally, some neuronal sets may not always be involved in sleep generation. By differentially driving the various neuronal sets shown in Fig. 16 by SFs, responses specific to sleep can be generated. (See ref. 106 for a numerical illustration of this concept). In contrast, most scenarios for driving the neuronal sets would involve the linkage of sleep to other physiological functions, which, in fact, is the usual case. In reference to the effects of SFs on sleep, the following points which are consistent with experimental findings can easily be envisioned from the model:

- 1) Some neuronal sets are more important than others for sleep propensity (have larger hypothetical output values (e.g., $x > y > z$). As a

consequence, some SFs are more important than others (e.g., B has a greater potential to enhance sleep than C).

2) If the output of two neuronal sets are held constant, stimulation of a third set could permit the sleep threshold to be reached; thus the exogenous administration of a SF could induce excess sleep.

3) In contrast, if neuronal sets x and y were at some minimal output level for sleep propensity, SF-D, which only interacts with neural set z, would not initiate sleep. Thus under certain experimental conditions, a SF may not initiate sleep while under others it would.

4) If one neuronal set was lesioned, total sleep propensity would be reduced. However, sleep would occur if the remaining sets were driven to a greater degree. This would also predict that after a lesion, the relative importance of various SF should shift. Further, an inherent feature of this model is that no individual neuronal set causes sleep, but all contribute to overall sleep propensity.

If the models in Figs. 15 and 16 are considered further within the context of dynamic properties of neurons (reviewed, 107), a more striking hypothesis is reached. It is: that sleep can, at different times, be caused by different neuronal sets (i.e., the elusive executive sleep center may be so because it is mobile). Many physiological systems affect sleep and, in some cases, the sensory neurons involved in those systems are altered by SFs. For example, sleep is closely linked to temperature regulation. IL1 can induce changes in firing rates of hypothalamic neurons (162). More importantly, some neurons that initially are insensitive to temperature changes become sensitive to heat after exposure to IL1 (41). This suggests that the intrinsic properties of these neurons are dynamic and subject to SF influence. Thus IL1

could change the sensory response characteristics of populations of neurons (this is one reason why there is a range of hypothetical outputs of the neuronal sets in Fig. 16). Furthermore, a single neuron can be a part of more than one sensory network (69) thus indicating that extrinsic properties are also dynamic. If a SF e.g., IL1, alters the responsiveness of neurons (left side of Fig. 16), such neuromodulatory actions could create dynamic neuronal networks that regulate sleep via constantly changing individual neural components (right side of Fig. 16).

Depending upon the specific physiological function driving sleep (e.g., temperature, appetite, circadian rhythms, etc.) the specific neuronal sets involved would vary. Under homeostatic conditions, variations in sleep-relevant sites would be minimal, thereby, leading to apparent sleep centers. However, under pathological conditions, sleep would occur but the specific neurons responsible for it could be different (e.g., sleep recovery after brain lesion). Furthermore, SFs that affect various aspects of physiology could alter sleep under some conditions (i.e., when neurons sensitive to them participate in the sleep network) but not under other conditions. Dynamic changes of electrical intrinsic properties of neurons have previously been recognized as possible mechanisms leading to cyclic variations of vigilance states (118). These dynamic electrical properties, though very important, are but one of many end products of chemical influences on the neuron.

It is thus proposed that animals experience sleep as a result of the activities of different neurons under different conditions. A vast number of lesion experiments support this view to the extent that if the animal lives, a recognizable form of sleep eventually occurs regardless of which neurons were lesioned.

Regardless of the specific mechanisms by which the brain is organized to produce sleep, the relatively recent explosive growth in information about SFs has led to new concepts about sleep regulation, some of which directly challenge long-held beliefs about sleep. The work on SFs has also emphasized that sleep must be considered within the context of other physiological processes. Finally, it is currently clear that several endogenous SFs are capable of enhancing sleep, that they do so by their direct (or indirect) effects on neurons and that their interactions are biochemically linked to each other. The regulation of these substances, therefore, has become an important facet of sleep regulation. It is also important since it will likely lead to the development of new safe somnogenic agents that induce natural sleep.

REFERENCES

1. Abemayor, E. and N. Sidell. Human neuroblastoma cell lines as models for the *in vitro* study of neoplastic and neuronal cell differentiation. *Environ. Health Perspec.* 80:3-15, 1989
2. Adrien, E. and C. Dugovic. PS-inducing factors and the noradrenergic system. In: *Endogenous Sleep Substances and Sleep Regulation*, Inoué, S. and A.A. Borbély, (eds). (Jap. Sci. Soc. Press), pp. 227-236, 1985.
3. Aggarwal, B.B., T.E. Eessalu and P.E. Hess. Characterization of receptors for human tumor necrosis factor and their regulation by γ -interferon. *Nature* 318: 665-667, 1985.
4. Antin, J., J. Gibbs, J. Holt, R.C Young and G.P. Smith. Cholecystokinin elicits the complete behavioral sequence of satiety in rats. *J. Comp. Physiol. Psychol.* 89:784-790, 1975.
5. Baek, L., N. Hoiby, J.B. Hertz and F. Espersen. Interactions between *Limulus* amoebocyte lysate and soluble antigens from *Pseudomonas aeruginosa* and *Staphylococcus aureus* studied by quantitative immunoelectrophoresis. *J. Clin. Microbiol.* 22: 229-237, 1985.
6. Baile, C. A., C.L. McLaughlin and M.A. Della-Fera. Role of cholecystokinin and opioid peptides in control of food intake. *Physiol. Rev.* 66: 172-234, 1986.
7. Barna, B.P., S.M. Chou, B. Jacobs, B. Yen-Lieberman and R.M. Ransohoff. Interferon beta impairs induction of HLA_{DR} antigen expression in cultured human astrocytes. *J. Neuroimmunol.* 23: 45-53, 1989.

8. Bendtzen, K., M. Svenson, V. Johsson, and E. Hippe. Auto antibodies to cytokines-friends or foes? *Immunol Today* 11: 167-169, 1990.
9. Benveniste, E.N., S.M. Sparacio and J.R. Bethea. Tumor necrosis factor alpha enhances interferon gamma-mediated class II antigen expression on astrocytes. *J. Neuroimmunol.* 25: 209-219, 1989.
10. Biavati, B., M. Vasta and J.G. Ferry. Isolation and characterization of "Methanospaera cuniculi" sp. nov. *Appl. Environ. Microbiol.* 54: 768-771, 1988.
11. Borbély, A.A. and I. Tobler. The search for an endogenous sleep substance. *TIPS* 1: 35-38, 1980.
12. Borbély, A.A. and I. Tobler. Endogenous sleep-promoting substances and sleep regulation. *Physiol. Rev.* 69: 605-670, 1989.
13. Breder, C.D. and C.B. Saper. Tumor necrosis factor immunoreactive innervation in the mouse brain. *Soc. for Neurosci. Absts.* 14: 1280, 1988.
14. Bush, J.W. Enzymatic lysis of the pseudomurein-containing methanogen *Methanobacterium formicium*. *J. Bacteriol.* 163: 27-36, 1985.
15. Cady, A.B., S. Kotani, T. Shiba, S. Kusumoto and J.M. Krueger. Somnogenic activities of synthetic lipid A. *Infec. Immunity* 57: 396-403, 1989.
16. Campbell, I.L., K. Bizilj, P.G. Colman, B.E. Tuch and L.C. Harrison. Interferon gamma induces the expression of HLA-A, B, C but not HLA-DR on human pancreatic beta cells. *J. Clin. Endocrinol. Metab.* 62: 1101-1109, 1986.

17. Chang, R.J. and S.H. Lee. Effects of interferon gamma and tumor necrosis factor alpha on the expression of an Ia antigen on a murine macrophage cell line. *J. Immunol.* 137: 2853-2856, 1986.
18. Chastrette, N. and R. Cespuglio. Influence of proopiomelanocortin-derived peptides on the sleep-waking cycle of the rat. *Neurosci. Lett.* 62: 365-370, 1985.
19. Chastrette, N., R. Cespuglio and M. Jouvet. Proopiomelanocortin (POMC)-derived peptides and sleep in the rat: Part 1 - Hypnogenic properties of ACTH derivatives. *Neuropeptides* 15: 61-74, 1990.
20. Cheifetz, S., J.A. Weatherbee, M.L.S. Tsang, J.K. Anderson, J.E. Mole, R. Lucas and J. Massague. The transforming growth factor beta system, a complex pattern of crossreactive ligands and receptors. *Cell* 48: 409-415, 1987.
21. Chung, I.Y. and E.N. Benveniste. Tumor necrosis factor alpha production by astrocytes - Induction by lipopolysaccharide, IFN gamma, and IL-1 beta. *J. Immunol.* 144: 2999-3007, 1990.
22. Conway de Macario, E., A.J.L. Macario, M.C. Magarinos, H. König, and O. Kandler. Dissecting the antigenic mosaic of the archaeobacterium *Methanobacterium thermoautotrophicum* by monoclonal antibodies of defined molecular specificity. *Proc. Natl. Acad. Sci. U.S.A.* 80: 6346-6350, 1983.
23. Crawley, J.N., S.E. Hays and S.M. Paul. Vagotomy abolishes the inhibitory effects of cholecystokinin on rat exploratory behaviors. *Eur. J. Pharmacol.* 73: 379-380, 1981.
24. Danguir, J. Intracerebroventricular infusion of somatostatin selectively increases paradoxical sleep in rats. *Brain Res.* 367: 26-30, 1986.

25. Danguir, J. and S. Nicolaidis. Circadian sleep and feeding patterns in the rat: possible dependence on lipogenesis and lipolysis. *Am. J. Physiol.* 208: E223-E230, 1980.
26. Danguir, J. and S. Nicolaidis. Chronic intracerebroventricular infusion of insulin causes selective increase of slow wave sleep in rats. *Brain Res.* 306: 97-103, 1984.
27. Datta, P.C. and M.G. King. Melatonin: effects on brain and behavior. *Neurosci. Biobehav. Rev.* 4: 451-458, 1980.
28. Davenne, D. and J. M. Krueger. Enhancement of quiet sleep in rabbit neonates by muramyl dipeptide. *Am. J. Physiol.* 253: R646-R654, 1987.
29. De Mesquita, S. and W. H. Haney. Effect of chronic intracerebroventricular infusion of cholecystokinin on respiration and sleep. *Brain Res.* 378: 127-132, 1986.
30. de Saint Hilaire-Kafi, Z., H. Depoortere and S. Nicolaidis. Does cholecystokinin induce physiological satiety and sleep? *Brain Res.* 488: 304-310, 1989.
31. De Wied, D., B. Bohus, W.H. Gispen, I. Urban and T.B. Van Wimersma-Greidanus. Hormonal influences on motivation, learning, and memory processes. In: *Hormones, Behavior and Psychopathology*, Sachar, E.J. (ed)., New York, pp. 1-29, 1976.
32. Della-Fera, M. A. and C.A. Baile. Cholecystokinin octa-peptide: continuous injections into the cerebral ventricles of sheep suppress feeding. *Science Wash. DC* 206: 471-473, 1979.
33. Desiraju, T. Effect of intraventricular administered prostaglandin E₁ on the electrical activity of cerebral cortex and

- behavior in the unrestrained monkey. *Prostaglandins* 3: 859-870, 1973.
34. Dhib-Jalbut, S. and D.E. McFarlin. Macrophages, microglia and other antigen-presenting cells in neurological disorders. *PNEI* 2: 86-95, 1989.
35. Dinarello, C. A. Interleukin-1. *Reviews of Infec. Dis.* 6: 51-95, 1974.
36. Drucker-Colin, R., J. Bernal-Pedraza, F. Fernandez-Cancino and A. Oksenberg. Is vasoactive intestinal polypeptide (VIP) a sleep factor? *Peptides* 5: 837-840, 1984.
37. Drucker-Colin, R.R., C.W. Spanis, J. Hunyadi, J.F. Sassin and J.L. McGaugh. Growth hormone effects on sleep and wakefulness in the rat. *Neuroendocrinology* 18: 1-8, 1975.
38. Dzoljic, M. R. Prostaglandins and sleep: awakening effects of prostaglandins and sleep pattern of essential fatty acids deficient (EFAD) rats. *Prostaglandins* 15: 317-323, 1978.
39. Dzoljic, M.R., O.E. Ukponmwan, J. Rupreht and J. Haffmans. Role of the enkephalinergic system in sleep studied by an enkephalinase inhibitor. In: *Sleep: Neurotransmitters and Neuromodulators*, Wauquier, A., J.M. Gaillard, J.M. Monti, and M. Kadulovacki (eds.), (New York), pp. 251-263, 1985.
40. Ehlers, C.L., T.K. Reed and S.J. Henriksen. Effects of corticotropin-releasing factor and growth hormone-releasing factor on sleep and activity in rats. *Neuroendocrinology* 42: 467-474, 1986.

41. Eisenman, J.S. Electrophysiology of the anterior hypothalamus: Thermoregulation and fever. In: *Milton Pyretic and Antipyretics*. Springer, Berlin, (ed.) pp. 187-217, 1982.
42. Fara, J.W., E.H Rubinstein and R.R. Sonnenschein. Visceral and behavioral responses to intraduodenal fat. *Science Wash. DC* 166: 110-111, 1969.
43. Farrar, W.L., J.M. Hill, A. Harel-Bellan and M. Vinocour. The immune logical brain. *Immunol. Rev.* 100: 361-377, 1987.
44. Fateur, V., E. Gouin and F. Dray. Growth hormone-releasing factor (GRF) stimulates PGE₂ production in rat anterior pituitary. Evidence for a PGE₂ involvement in GRF-induced GH release. *Biochem. Biophys. Res. Comm.* 126: 725-733, 1985.
45. Fencl, V., G. Koski and J.R. Pappenheimer. Factors in cerebrospinal fluid from goats that affect sleep and activity in rats. *J. Physiol. Lond.* 216: 565-589, 1971.
46. Feng, J., M. Price, J. Cohen and E. Satinoff. Prostaglandin fevers in rats: regulated change in body temperature or change in regulated body temperature. *Am. J. Physiol.* 257: R695-R699, 1989.
47. Flood, J.F., G.E. Smith and J.E. Morley. Modulation of memory processing by cholecystokinin: dependence on the vagus nerve. *Science Wash. DC* 236: 832-834, 1987.
48. Flynn, A. Expression of Ia and the production of interleukin-1 by peritoneal exudate macrophages activated *in vivo* by steroids. *Life Sci.* 38: 2455-2600, 1986.
49. Fontana, A., W. Fiers and H. Wekerle. Astrocytes present myelin basic protein to encephalitogenic T-cell lines. *Nature* 307: 273-276, 1984.

50. Fontana, A., A. Kristensen, R. Dubs, D. Gemsa and E. Weber.
Production of prostaglandin E and an interleukin-like factor by
cultured astrocytes and C6 glioma cells. *J. Immunol.* 129: 2413-
2419, 1982.
51. Försterman, U., R. Heldt and G. Hertting. Effects of intra-
cerebroventricular administration of prostaglandin D₂ on
behavior, blood pressure and body temperature as compared to
prostaglandins E₂ and F_{2a}. *Psychopharmacology* 80: 365-370, 1983.
52. Förstermann, U., R. Heldt and G. Hertting. Studies on the
mechanism of central cardiovascular and temperature responses
to prostaglandin D₂. *Prostaglandins, Leukotrienes and Medicine*
18: 301-308, 1985.
53. Froham, E.M., T.C. Froham, B. Vayuvegula, S. Gupta and S. van den
Noot. Vasoactive intestinal polypeptide inhibits the expression
of the MHC class II antigens on astrocytes. *J. Neurol. Sci.* 88:
339-346, 1988.
54. Frohman, E.M., T.C. Frohman, M.L. Dustin, B. Vayuvegula, B. Choi,
A. Gupta, S. van den Noort and S. Gupta. The induction of inter-
cellular adhesion molecule 1 (ICAM-1) expression on human fetal
astrocytes by interferon gamma, tumor necrosis factor alpha,
lymphotoxin, and interleukin-1: relevance to intracerebral
antigen presentation. *J. Neuroimmunol.* 23: 117-124, 1989.
55. Gerrard, T.L., T.R. Cupps, C.H. Jurgensen and A.S. Fauci.
Hydrocortisone-mediated inhibition of monocyte antigen
presentation: Dissociation of inhibitory effect and expression of
DR antigens. *Cell. Immunol.* 85: 330-339, 1984.

56. Gerrard, T.L., C.H. Jurgensen and A.S. Fauci. Differential effect of monoclonal anti-DR antibody on monocytes in antigen- and mitogen-stimulated responses: mechanism of inhibition and relationship to interleukin-1 secretion. *Cell. Immunol.* 82: 394-402, 1983.
57. Gibbs, J., R.C. Young and G.P. Smith. Cholecystokinin decreases food intake in rats. *J. Comp. Physiol. Psychol.* 84: 488-495, 1973.
58. Gibbs, J., R.C. Young and G.P. Smith. Cholecystokinin elicits satiety in rats with open gastric fistulas. *Nature Lond.* 245: 323-325, 1973.
59. Giulian, D., T.J. Baker, L.N. Shih and L.B. Lachman. Interleukin-1 of the central nervous system is produced by ameboid microglia. *J. Exp. Med.* 164: 594-604, 1986.
60. Graf, M.V. and A.J. Kastin. Delta-sleep-inducing peptide (DSIP): An update. *Peptides* 7: 1165-1187, 1987.
61. Graf, M.V., J.A. Kastin, D.H. Coy and A.J. Fischman. Delta-sleep-inducing peptide reduces CRF-induced corticosterone release. *Neuroendocrinology* 41: 353-356, 1985.
62. Grinker, J.A., B.S. Schneider, G. Ball, A. Cohen, A. Strohmayer and J. Hirsch. Cholecystokinin (CCK-8) and bombesin (BBS) intracranial injections and satiety in rats. *Fed. Proc.* 39: 501, 1980.
63. Haubrich, D. R., J. Perez-Cruet and W. D. Reid. Prostaglandin E₁ causes sedation and increases 5-hydroxy tryptamine turnover in the rat brain. *Br. J. Pharmacol.* 48: 80-87, 1973.
64. Hayaishi, O. Sleep-wake regulation by prostaglandins D₂ and E₂. *J. Biol. Chem.* 263: 14593-14596, 1988.

65. Heuser, G., G.M. Ling and M. Kluver. Sleep induction by progesterone in the preoptic area in cats. *Electroenceph. Clin. Neurophysiol.* 22: 122-127, 1967.
66. Hickey, W.F., B. Hsu and H. Kimura. T-lymphocyte entry into the rat central nervous system (CNS). *FASEB J.* 3: A482, 1989.
67. Holt, S.J., R.F. Grimble and D.A. York. Tumor necrosis factor α and lymphotoxin have opposite effects on sympathetic efferent nerves to brown adipose tissue by direct action in the central nervous system. *Brain Res.* 497:183-186, 1989.
68. Honda, K., Y. Komoda and S. Inoué. Oxidized glutathione as another active component of sleep-promoting substance (SPS) II. Somnogenic activity in unrestrained rats. *Sleep Res.* 19: 61, 1990.
69. Hooper, S.L. and M. Moulins. Switching of a neuron from one network to another by sensory-induced changes in membrane properties. *Science* 244: 1587-1589, 1989.
70. Horiguchi, S., R. Ueno, M. Hyodo and O. Hayaishi. Alterations in nociception after intracisternal administration of prostaglandin D₂, E₂, or F_{2a} to conscious mice. *Europ. J. Pharmacol.* 122: 173-179, 1986.
71. Horne, J.A., J.E. Percival and J.R. Traynor. Aspirin and lunar sleep. *Electroencephalog. Clin. Neurophysiol.* 49: 409-413, 1980.
72. Horton, E.W. Actions of prostaglandins E₁, E₂, and E₃ on the central nervous system. *Brit. J. Pharmacol.* 22: 189-192, 1964.
73. Houghton, A.N., T.M. Thomson, D. Gross, H.F. Oettgen and L.J. Old. Surface antigen of melanoma and melanocytes. *J. Exp. Med.* 160: 255-269, 1984.

74. Houpt, T. R., S.M. Anika, N.C. Wolff. Satiety effects of cholecystokinin and caerulein in rabbits. *Am. J. Physiol.* 235: R23-R28; 1978.
75. Inoué, S., K. Honda, Y. Komoda, K. Uchizono, R. Ueno and O. Hayaishi. Differential sleep-promoting effects of five sleep substances nocturnally infused in unrestrained rats. *Proc. Natl. Acad. Sci. USA* 81: 6240-6244, 1984.
76. Inoué, S., K. Honda, Y. Komoda, K. Uchizono, R. Ueno and O. Hayaishi. Little sleep-promoting effect of three sleep substances diurnally infused in unrestrained rats. *Neurosci. Letters* 49: 207-211, 1984.
77. Johannsen, L., H. Labischinski, R. Reinicke and P. Giesbrecht. Changes in the chemical structure of walls of *Staphylococcus aureus* grown in the presence of chloramphenicol. *FEMS Lett.* 16: 313-316, 1983.
78. Johannsen, L., J. Wecke, F. Obál, Jr. and J.M. Krueger. Macrophages produce somnogenic and pyrogenic muramyl peptides during the digestion of staphylococci. *Am. J. Physiol.* (in press).
79. Johannsen, L., L.A. Toth, R.S. Rosenthal, M.R. Opp, F. Obál, Jr., A.B. Cady and J.M. Krueger. Somnogenic, pyrogenic, and hematologic effects of bacterial peptidoglycan. *Am. J. Physiol.* 259: R182-R186, 1990.
80. Johannsen, L., R.S. Rosenthal, S.A. Martin, A.B. Cady, F. Obál, Jr., M. Guinand and J.M. Krueger. 1989. Somnogenic activity of O-acetylated and dimeric muramyl peptides. *Infect. Immun.* 57: 2726-2732, 1989.

81. Johnson, W.J., A. Kelley, J.R. Connor, B.J. Dalton and P.C. Meunier. Inhibition of IFN gamma-induced Ia antigen expression on synovial fibroblasts by IL-1. *J. Immunol.* 143: 1614-1618, 1989.
82. Joseph, J., R.L. Knobler, C. D'Imperio and F.D. Lubin. Down-regulation of interferon gamma-induced class II expression on human glioma cells by recombinant interferon beta: effects of dosage treatment schedule. *J. Neuroimmunol.* 20: 39-44, 1988.
83. Jouvett, M. Neuromédiateurs et facteurs hypnogenes. *Rev. Neurol. (Paris)* 140: 389-400, 1984.
84. Kandler, O. and H. König. Cell Envelopes of Archaeobacteria. In: C.R. Woese and R.S. Wolfe (ed.). *The bacteria. A treatise on structure and function, Vol. VIII. Archaeobacteria.* Academic Press, London, pp. 413-457, 1985.
85. Kanke, M., G.H. Simmons, D.L. Weiss, B.A. Bivins and P.P. DeLuca. 1980. Clearance of ¹⁴¹Ce-labeled microspheres from blood and distribution in specific organs following intravenous and intra-arterial administration in beagle dogs. *J. Pharm. Sci.* 69: 755-762, 1980.
86. Kanke, M., R.G. Geissler, D. P well, A. Kaplan and P.P. DeLuca. Interaction of microspheres with blood constituents. III. Macrophage phagocytosis of various types of polymeric drug carriers. *J. Parenter. Sci. Technol.* 37: 157-165, 1988.
87. Kapás, L., F. Obál, Jr, P. Alföldi, G. Rubicsek, B. Penkeand and F. Obál. Effects of nocturnal intraperitoneal administration of cholecystokinin in rats: simultaneous increase in sleep, increase in EEG slow-wave activity, reduction of motor activity, suppres-

- sion of eating, and decrease in brain temperature. *Brain Res.* 438: 155-164, 1988.
88. Kapás, L., F. Obál, Jr, B. Penke and F. Obál. Cholecystokinin-octapeptide-induced hypothermia in rats: dose-effect and structure-effect relationships, effect of ambient temperature, pharmacological interactions and tolerance. *Neuropharmacology* 26: 131-137, 1987.
89. Katz, B., M. Sofonio, P.D. Lyden and M.D. Mitchell. Prostaglandin concentrations in cerebrospinal fluid of rabbits under normal and ischemia conditions. *Stroke* 19: 349-351, 1988.
90. Keller, M., R. Jackisch, A. Seregi and G. Hertting. Comparison of prostanoid forming capacity of neuronal and astroglial cells in primary cultures. *Neurochem. Int.* 7: 655-665, 1985.
91. Kiener, A., H. König, J. Winter and T. Leisinger. Purification and use of *Methanobacterium wolfei* pseudomurein endopeptidase for lysis of *Methanobacterium thermoautotrophicum*. *J. Bacteriol.* 169: 1010-1016, 1987.
92. Koch, N., G.H.W. Wong and J.W. Schrader. Ia antigens and associated invariant chain are induced simultaneously in lines of T-dependent mast cells by recombinant interferon gamma. *J. Immunol.* 132: 1361-1369, 1984.
93. Koella, W.P. The organization and regulation of sleep. *Experientia (Basel)* 40: 309-338, 1984.
94. Konno, H., T. Yamamoto, Y. Iwasaki, H. Suzuki, T. Saito and H. Terunuma. Wallerian degeneration induces Ia-antigen expression in the rat brain. *J. Neuroimmunol.* 2: 151-159, 1989.

95. König, H. Archaeobacterial cell envelopes. *Can. J. Microbiol.* 34: 395-406, 1988.
96. Krueger, J.M., J.R. Pappenheimer and M.L. Karnovsky. Sleep-promoting effects of muramyl peptides. *Proc. Natl. Acad. Sci. USA* 79: 6102-6106, 1982.
97. Krueger, J.M., J.R. Pappenheimer and M.L. Karnovsky. The composition of sleep-promoting factor isolated from human urine. *J. Biol. Chem.* 257: 1664-1669, 1982.
98. Krueger, J.M., J. Walter, C. Dinarello, C. Wolff and L. Chedid. Sleep-promoting effects of endogenous pyrogen (interleukin-1). *Am. J. Physiol.* 246: R994-R999, 1984.
99. Krueger, J.M., J. Walter, M.L. Karnovsky, L. Chedid, J.P. Choay, P. Lefrancier and E. Lederer. Muramyl peptides-variation of somnogenic activity with structure. *J. Exp. Med.* 159: 68-76, 1984.
100. Krueger, J. M. Muramyl peptides and interleukin-1 as promoters of slow-wave sleep. In: *Endogenous Sleep Substances and Sleep Regulation*. S. Inoué and A. A. Borbély (eds). Japan Scientific Societies Press, Tokyo, pp. 181-192, 1985.
101. Krueger, J. M., S. Kubillus, S. Shoham and D. Davenne. Enhancement of slow-wave sleep by endotoxin and lipid A. *Am. J. Physiol.* 251: R591-R597, 1986.
102. Krueger, J.M., D. Davenne, J. Walter, S. Shoham, S.L. Kubillus, R.S. Rosenthal, S.A. Martin and K. Biemann. Bacterial peptidoglycans as modulators of sleep. II. Effects of muramyl peptides on the structure of rabbit sleep. *Brain Res.* 403: 258-266, 1987.

103. Krueger, J.M., C.A. Dinarello, S. Shoham, D. Davenne, J. Walter and S. Kubillus. Interferon alpha-2 enhances slow-wave sleep in rabbits. *Int. J. Immunopharmac.* 9: 23-30, 1987.
104. Krueger, J.M., R.S. Rosenthal, S.A. Martin, J. Walter, D. Davenne, S. Shoham, S.L. Kubillus and K. Biemann. Bacterial peptidoglycans as modulators of sleep. I. Anhydro forms of muramyl peptides enhance somnogenic potency. *Brain Res.* 403: 249-257, 1987.
105. Krueger, J.M and L. Johannsen. Bacterial products, cytokines and sleep. *J. Rheumatol.* (Suppl. 19) 16: 52-57, 1989.
106. Krueger, J.M., F. Obál, Jr., M. Opp, L.A. Toth, L. Johannsen and A.B. Cady. Somnogenic cytokines and models concerning their effects on sleep. *Yale J. Biol. Med.* 63: 157-172, 1990.
107. Krueger, J.M., M. Opp, L.A. Toth and L. Kapás. Immune regulation, hormones and sleep. In: *Sleep '90*. J. Horne, (ed.), Pontenagel Press, Bochum, (in press).
108. Kuehl, F.A., Jr. and F.A. Egan. Prostaglandins, arachidonic acid, and inflammation. *Science* 210: 978-983, 1980.
109. Kunkel, S.L., S.W. Chensue and S.H. Phan. Prostaglandins as endogenous mediators of interleukin-1 production. *J. Immunol.* 136: 186-192, 1986.
110. Labischinski, H., G. Barnickel, B. Leps, H. Bradaczek and P. Giesbrecht. Initial data for the comparison of murein and pseudomurein conformations. *Arch. Microbiol.* 127: 195-201, 1980.
111. Labischinski, H., G. Barnickel, H. Bradaczek and P. Giesbrecht. On the secondary and tertiary structure of murein. *Eur. J. Biochem.* 95: 147-155, 1979.

112. Laychock, S. G., D. N. Johnson and L.S. Harris. PGD₂ effects on rodent behavior and EEG patterns in cats. *Pharmacology Biochem. and Behav.* 12: 747-754, 1980.
113. Leeuwenberg, J.F.M., J. Van Damme, A. Meager, G.M.A.A. Jeunhomme and W.A. Buurman. Effects of tumor necrosis factor on the interferon gamma induced major histocompatibility complex class II antigen expression by human endothelial cells. *Eur. J. Immunol.* 18: 1469-1472, 1988.
114. Legendre, R. and H. Pieron. Recherches sur le besoin de sommeil consecutif a une vielle prolongee. *Z. Allg. Physiol.* 14: 235-262, 1913.
115. Leps, B., G. Barnickel and H. Labischinski. Structural studies on the bacterial cell wall peptidoglycan pseudomurein. I. Conformational energy calculations on the glycan strands in C1 conformation and comparison with murein. *J. Theor. Biol.* 107: 85-114, 1984.
116. Leps, B., H. Labischinski, G. Barnickel, H. Bradaczek and P. Giesbrecht. A new proposal for the primary and secondary structure of the glycan moiety of pseudomurein. Conformational energy calculations on the glycan strands with talosaminuronic acid in 1C conformation and comparison with murein. *Eur. J. Biochem.* 144: 279-286, 1984.
117. Lipton, J.M., J.R. Glynn. Central administration of peptides alters thermoregulation in the rabbit. *Peptides* 1: 15-18, 1980.
118. Llinas, R.R. The intrinsic electrophysiological properties of mammalian neurons: Insights into central nervous system function. *Science* 242: 1654-1663, 1988.

119. Majde, J.A., R.K. Brown, M.W. Jones, C.W. Dieffenbach, N. Maitra, J.M. Krueger, A.B. Cady, C.W. Smitka and H.F. Maasab. Detection of toxic viral-associated double-stranded RNA (dsRNA) in influenza-infected lung. *Microbial Pathogenesis* (in press).
120. Male, D. and G. Pryce. Synergy between interferons and monokines in MHC induction on brain endothelium. *Immunol. Lett.* 17: 267-272, 1988.
121. Mansbach, R.S. and D.N. Lorenz. Cholecystokinin (CCK-8) elicits prandial sleep in rats. *Physiol. Behav.* 30: 179-183, 1983.
122. Manthorpe, M., R. Adler and S. Varon. Development, reactivity and GFA immunofluorescence of astroglia-containing monolayer cultures from rat cerebrum. *J. Neurocytol.* 8: 605-621, 1979.
123. Masek, K., O. Kadlecova and N. Poschlova. Effect of intracisternal administration of prostaglandin E₁ on waking and sleep in the rat. *Neuropharmacol.* 15: 491-494, 1976.
124. Massa, P.T. and V.T. Meulen. Analysis of Ia induction on Lewis rat astrocytes *in vitro* by virus particles and bacterial adjuvants. *J. Neuroimmunol.* 13: 259-271, 1987.
125. Massa, P.T., A. Schimpl, E. Wecker and V.T. Meulen. Tumor necrosis factor amplifies measles virus-mediated Ia induction on astrocytes. *Proc. Natl. Acad. Sci. USA (Immunology)* 84: 7242-7245, 1987.
126. Matsumura, H., K. Honda, W.S. Choi, S. Inoué, T. Sukai and O. Hayaishi. Evidence that brain prostaglandin E₂ is involved in physiological sleep-wake regulation in rats. *Proc. Natl. Acad. Sci. USA* 86: 5666-5669, 1989.

127. Matsumura, H., Y. Goh, R. Ueno, T. Sakai and O. Hayaishi. Awakening effect of PGE₂ microinjected into the preoptic area of rats. *Brain Res.* 444: 265-272, 1988.
128. Melhus, O., T.J. Koerner and D.O. Adams. Effects of TNF alpha on the expression of class II MHC molecules in macrophages induced by IFN gamma: evidence for suppression at the level of transcription. *J. Leukocyte Biol.* 49: 21-28, 1991.
129. Miller, T.L. and M.J. Wolin. Methanogens in human and animal intestinal tracts. *Syst. Appl. Microbiol.* 7: 223-229, 1986.
130. Miller, T.L., M.J. Wolin and E.A. Kusel. Isolation and characterization of methanogens from animal feces. *Syst. Appl. Microbiol.* 8: 234-238, 1986.
131. Morimoto, A., N. Murakami, T. Nakamori and T. Watanabe. Multiple control of fever production in the central nervous system of rabbits. *J. Physiol.* 397: 269-280, 1988.
132. Morris, A.G. and P.T. Tomkins. Interactions of interferons in the induction of histocompatibility antigens in mouse fibroblasts and glial cells. *Immunol.* 67: 537-539, 1989.
133. Naito, K., H. Osama, R. Ueno, O. Hayaishi, K. Honda and S. Inoué. Suppression of sleep by prostaglandin synthesis inhibitors in unrestrained rats. *Brain Res.* 453: 329-336, 1988.
134. Nistico, G. and E. Marley. Central effects of prostaglandin E₁ in adult fowls. *Neuropharmacol.* 12: 1009-1016, 1973.
135. Nistico, G. and E. Marley. Central effects of prostaglandins E₂, A₁ and F_{2a} in adult fowls. *Neuropharmacology* 15: 737-741, 1976.

136. O'Dorisio, M.S., C.L. Wood and T.M. O'Dorisio. Vasoactive intestinal peptide and neuropeptide modulation of the immune system. *J. Immunol.* 135: 792s-795s, 1985.
137. Obál, Jr., F. Effects of peptides (DSIP, DSIP analogues, VIP, GRF and CCK) on sleep in the rat. *Neuropharmacol.* (S4) 9: 459-461, 1986.
138. Obál Jr., F., P. Alföldi, A.B. Cady, L. Johannsen, G. Sáry, J.M. Krueger. Growth hormone-releasing factor enhances sleep in rats and rabbits. *Am. J. Physiol.* 255: R310-R316, 1988.
139. Obál, Jr., F., M.R. Opp, A.B. Cady, L. Johannsen, A.E. Postlethwaite, H.M. Poppleton, J.M. Seyer and J.M. Krueger. Interleukin-1 α and an interleukin-1 β fragment are somnogenic. *Am. J. Physiol.* 259: R439-446, 1990.
140. Onoe, H., R. Ueno, I. Fujita, H. Nishino, Y. Oomura and O. Hayaishi. Prostaglandin D₂, a cerebral sleep-inducing substance in monkeys. *Proc. Natl. Acad. Sci. USA* 85: 4082-4086, 1988.
141. Opp, M.R., F. Obál, Jr. and J.M. Krueger. Effects of alpha-MSH on sleep, behavior, and brain temperature: interactions with IL1. *Am. J. Physiol.* 255: R914-R922, 1988.
142. Opp, M.R., F. Obál, Jr., A.B. Cady, L. Johannsen and J.M. Krueger. Interleukin-6 is pyrogenic but not somnogenic. *Physiol. Behav.* 45: 1069-1072, 1989.
143. Opp, M., F. Obál, Jr. and J. M. Krueger. Corticotropin releasing factor attenuates interleukin-1-induced sleep and fever in rabbits. *Am. J. Physiol.* 257: R528-R535, 1989.

144. Opp, M.R. and J.M. Krueger. Effects of an interleukin-1 receptor antagonist on recovery sleep of rabbits after total sleep deprivation. *Sleep Res.* (in press).
145. Opp, M.R. and J.M. Krueger. An interleukin-1 receptor antagonist blocks interleukin-1 induced sleep and fever. *Am. J. Physiol.* (in press).
146. Pappenheimer, J. R., G. Koski, V. Fencel, M.L. Karnovsky and J. Krueger. Extraction of sleep-promoting factor S from cerebrospinal fluid and from brains of sleep-deprived animals. *J. Neurophysiol.* 38: 1299-1311, 1975.
147. Passaro, Jr., E., H. Debas, W. Oldendorf and T. Yamada. Rapid appearance of intraventricularly administered neuropeptides in the peripheral circulation. *Brain Res.* 241: 335-340, 1982.
148. Pavel, G. Pineal vasotocin and sleep: involvement of serotonin containing neurons. *Brain Res. Bull.* 4: 731-734, 1979.
149. Pederson, R.A. and J.C. Brown. Effect of cholecystikinin, secretin, and gastric inhibitory polypeptide on insulin release from the isolated perfused rat pancreas. *Can. J. Physiol. Pharmacol.* 57: 1233-1237, 1979.
150. Piguet, V., S. Carrel, A.C. Diserens, J.P. Mach and N. de Tribolet. Heterogeneity of the induction of HLA_{DR} expression by human immune interferon on glioma cell lines and their clones. *JNCI* 76: 223-228, 1986.
151. Posadas-Andrews, A., O. Prospéro-García, J.A. Rojas-Ramírez. CCK-8 effects on sleep and feeding. *Soc. Neurosci. Abstr.* 15, part 2: 1068, 1989.

152. Prospéro-García, O., T. Ott and R. Drucker-Colín. Cerebroven-tricular infusion of cholecystokinin (CCK-8) restores REM sleep in parachlorophenylalanine (PCPA)-pretreated cats. *Neurosci. Lett.* 78: 205-210, 1987.
153. Puizillout, J.J., G. Gaudin-Chazal and H. Bras. Vagal mechanisms in sleep regulation. *Exptl. Brain Res. Suppl* 8: 19-38, 1984.
154. Radulovacki, M. and R.M. Virus. Purine, 1-methylisoguanosine and pyrimidine compounds and sleep in rats. In: *Sleep: Neurotransmitters and Neuromodulators*, Wauquier, A., J.M. Gaillard, J.M. Monti, and M. Radulovacki, (eds.), (New York), pp. 251-263, 1985.
155. Riou, F., R. Cespuglio and M. Jouvet. Endogenous peptides and sleep in the rat: II Peptides without significant effect on the sleep-waking cycle. *Neuropeptides* 2: 255-264, 1982.
156. Sach, J., J. Ungar, P.G. Waser and A. Borbély. Factors in cerebrospinal fluid affecting motor activity in the rat. *Neurosci. Lett.* 2: 83-86, 1976.
157. Sallanon, M., C. Buda, M. Janin and M. Jouvet. Implication of serotonin in sleep mechanisms: induction, facilitation? In: *Sleep, Neurotransmitters and Neuromodulators*, Wauquier, A., J.M. Gaillard, J.M. Monti and M. Radulovacki, (eds.), (New York), pp. 135-140, 1985.
158. Sangiah, S., D.F. Caldwell, M.J. Villeneuve and J.J. Clancy. Sleep: sequential reduction of paradoxical (REM) and elevation of slow-wave (NREM) sleep by a non-convulsive dose of insulin in rats. *Life Sci.* 31: 763-769; 1982.

159. Sawada, M., N. Kondo, A. Suzumura and T. Marunouch. Production of tumor necrosis factor alpha by microglia and astrocytes in culture. *Brain Res.* 491: 394-397, 1989.
160. Schluesener, H.J. Transforming growth factors type beta1 and beta2 suppress rat astrocyte autoantigen presentation and antagonize hyperinduction of class II major histocompatibility complex antigen expression by interferon gamma and tumor necrosis factor alpha. *J. Neuroimmunol.* 27: 41-47, 1990.
161. Schoenenberger, G.A. Characterization, properties and multi-variate functions of delta-sleep-inducing peptide (DSIP). *Eur. Neurol.* 23: 321-345, 1984.
162. Shibata, M. Hypothalamic neuronal responses to cytokines. *Yale J. Biol. and Med.* 63: 147-156, 1990.
163. Shoham, S. and J.M. Krueger. Muramyl dipeptide-induced sleep and fever: effects of ambient temperature and time of injections. *Am. J. Physiol.* 255: R157-R165, 1988.
164. Shoham, S., D. Davenne, A.B. Cady, C.A. Dinarello and J.M. Krueger. Recombinant tumor necrosis factor and interleukin-1 enhance slow-wave sleep. *Am. J. Physiol.* 253: R142-R149, 1987.
165. Smith, G.P., C. Jerome, B.J. Cushin, R. Eterno and K.J. Simansky. Abdominal vagotomy blocks the satiety effect of cholecystokinin in the rat. *Science Wash. DC* 213: 1036-1037, 1981.
166. Snyder, D.S., D.I. Beller and E.R. Unanue. Prostaglandins modulate macrophage Ia expression. *Nature* 299: 163-165, 1982.
167. Steiniger, B., P. Falk and P.H. Van der Meide. Interferon gamma *in vivo*. Induction and loss of class II MHC antigens and immature

- myelomonocytic cells in rat organs. *Eur. J. Immunol.* 18: 661-669, 1988.
168. Stenson, W.F. and C.W. Parker. Prostaglandins, macrophages, and immunity. *J. Immunol.* 125: 1-5, 1980.
169. Sternberg, E.M., J. Trial and C.W. Parker. Effect of serotonin on murine macrophages: suppression of Ia expression by serotonin and its reversal by 5-HT₂ serotonergic receptor antagonists. *J. Immunol.* 137: 276-282, 1986.
170. Stimpson, S.A., R.R. Brown, S.K. Anderle, D.G. Klapper, R.L. Clark, W.J. Cromartie and J.H. Schwab. Arthropathic properties of cell wall polymers from normal flora bacteria. *Infect. Immun.* 51: 240-249, 1986.
171. Sztein, M.B., P.S. Steeg, M.J. Howard and J.J. Oppenheim. Regulation of human peripheral blood monocyte DR antigen expression *in vitro* by lymphokines and recombinant interferons. *J. Clin. Invest.* 73: 556-565, 1984.
172. Takahashi Y., S. Usui, S. Ebihara and Y. Honda. Effects of continuous infusions of TRH and GIF on circadian rhythm parameters of sleep, ambulation, eating, and drinking in rats. In: *Endogenous Sleep Substances and Sleep Regulation*, Inoué, S. and A.A. Borbély, (eds.), Japan Sci. Soviet Press, Tokyo, pp. 227-236, 1985.
173. Todd, I., R. Pujol-Borrell, L.J. Hammond, G.F. Bottazzo and M. Feldmann. Interferon gamma induces HLA_{DR} expression by thyroid epithelium. *Clin. Exp. Immunol.* 61: 265-273, 1985.

174. Toth, L.A. and J.M. Krueger. Alteration of sleep in rabbits by *Staphylococcus aureus* infection. *Infect. Immunity* 56: 1785-1791, 1988.
175. Toth, L.A. and J.M. Krueger. Effects of microbial challenge on sleep in rabbits. *FASEB J.* 3: 2062-2066; 1989.
176. Traugott, U. and P. Lebon. Interferon gamma and Ia antigen are present on astrocytes in active chronic multiple sclerosis lesions. *J. Neurol. Sci.* 84: 257-264, 1988.
177. Traugott, U., D.E. McFarlin and C.S. Raine. Immunopathology of the lesion in chronic relapsing experimental autoimmune encephalomyelitis in the mouse. *Cell. Immunol.* 99: 395-410, 1986.
178. Ueno, R., K. Honda, S. Inoué and O. Hayaishi. Prostaglandin D₂, a cerebral sleep-inducing substance in rats. *Proc. Natl. Acad. Sci. USA* 80: 1735-1737, 1983.
179. Ueno, R., Y. Ishikawa, T. Wakayama and O. Hayaishi. Prostaglandin D₂ induces sleep when microinjected into the preoptic area of conscious rats. *Biochem. Biophys. Res. Comm.* 109: 576-582, 1982.
180. Unger, R.H., H. Ketterer, J. Dupré and A.M. Eisentraut. The effects of secretin, pancreozymin, and gastrin on insulin and glucagon secretion in anesthetized dogs. *J. Clin. Inv.* 46: 630-645, 1967.
181. Ursin, R. Endogenous sleep factors. *Exp. Brain Res. (Suppl.)*, 8: 118-132, 1984.
182. Verbalis, J.G., M.J. McCann, C.M. McHale and E.M. Stricker. Oxytocin secretion in response to cholecystokinin and food: differentiation of nausea from satiety. *Science Wash. DC* 232: 1417-1419, 1986.

183. Von Economo, C. Sleep as a problem of localization. *J. Nerv. Ment. Dis.* 71: 249-259, 1930.
184. Wagner, C.R., R.M. Vetto and D.R. Burger. Expression of I-region-associated antigen (Ia) and interleukin-1 by subcultured human endothelial cells. *Cell. Immunol.* 93: 91-104, 1985.
185. Warren, M.K. and S.N. Vogel. Opposing effects of glucocorticoids on interferon gamma-induced murine macrophage Fc receptor and Ia antigen expression. *J. Immunol.* 134: 2462-2469, 1985.
186. Wecke, J., L. Johannsen and P. Giesbrecht. Reduction of wall degradability of clindamycin-treated staphylococci within macrophages. *Infect. Immun.* 58: 197-204, 1990.
187. Wildfeuer, A., B. Heymer, K.H. Schleifer and O. Haferkamp. Investigations on the specificity of the Limulus test for the detection of endotoxin. *Appl. Microbiol.* 28: 867-871, 1974.
188. Williams, K.A., D.N.J. Hart, J.W. Fabre and P.J. Morris. Distribution and quantitation of HLA-ABC and DR (Ia) antigens on human kidney and other tissues. *Transplantation* 29: 274-279, 1980.
189. Wright, J.R., Jr. and H.R. Epstein. Tumor necrosis factor enhances interferon-induced Ia antigen expression on murine islet parenchymal cells. *Am. J. Pathol.* 130: 427-430, 1988.
190. Yamamoto, K., T. Miwa, R. Ueno and O. Hayaishi. Muramyl dipeptide-elicited production of PGD₂ from astrocytes in culture. *Biochem. Biophysic Res. Comm.* 156: 882-888, 1988.
191. Yamasu, K., H. Onoe, G. Soma, H. Oshima and D. Mizuno. Secretion of tumor necrosis factor during fetal and neonatal development of

- the mouse: ontogenic inflammation. *J. Biol. Response Modifiers* 8: 644-655, 1989.
192. Yamasu, K., Y. Shimada, M. Sakaizumi, G.I. Soma and D.-I. Mizono. Activation of the systemic production of tumor necrosis factor after exposure to acute physical stress. *Third Internat. Conf. on TNF and Related Cytokines Absts.*, p. 174, 1990.
193. Zetler, G. Cholecystokinin octapeptide, caerulein and caerulein analogues: effects on thermoregulation in the mouse. *Neuropharmacology* 21: 795-801, 1982.
194. Zini, I., E.M. Pich, K. Fuxe, P.L. Lenzi, L.F. Agnati, A. Harfstrand, V. Mutt, K. Tatemoto and M. Moscara. Actions of centrally administered neuropeptide Y on EEG activity in different rat strains and in different phases of their circadian cycle. *Acta. Physiol. Scand.* 122: 71-77, 1984.
195. Zuber, P., M.C. Kuppner and N. De Tribolet. Transforming growth factor beta2 down-regulates HLA_{DR} antigen expression on human malignant glioma cells. *Eur. J. Immunol.* 18: 1623-1626, 1988.

TABLE 1: Effects of TNF α , TNF β , TNF α fragments and F-MLP peptide on rabbit sleep-wake activity and brain temperatures.

	dose (ug)	n	NREMS ⁺		REMS		T _{br}
			Cont.	Exp.	Cont.	Exp.	
TNF α	0.005	5	41.3 \pm 1.6	41.0 \pm 1.3	5.6 \pm 1.2	5.1 \pm 0.7	0.12 \pm 0.14
	0.05	8	39.1 \pm 2.4	46.3 \pm 2.2*	4.3 \pm 0.8	4.0 \pm 0.5	0.55 \pm 0.10*
	0.5	8	44.3 \pm 1.6	57.0 \pm 3.3*	3.8 \pm 0.7	1.4 \pm 0.4*	0.82 \pm 0.17*
	5.0	4	44.3 \pm 1.1	68.7 \pm 4.2*	4.1 \pm 0.7	0.9 \pm 0.4*	2.00 \pm 0.26*
TNF β	0.0005	7	43.2 \pm 1.6	47.5 \pm 1.4*	5.5 \pm 0.9	5.0 \pm 0.8	0.77 \pm 0.08
	0.005	6	41.5 \pm 1.6	44.9 \pm 2.8	6.3 \pm 0.7	5.1 \pm 0.5	-0.22 \pm 0.05*
	0.05	7	42.5 \pm 1.9	44.8 \pm 2.1	5.0 \pm 0.8	6.1 \pm 0.5	0.23 \pm 0.08*
	0.2	6	41.1 \pm 1.5	56.3 \pm 3.7*	6.3 \pm 0.7	3.5 \pm 0.6*	1.02 \pm 0.09*
TNF α_{10-36}	5	5	40.1 \pm 1.7	42.4 \pm 1.7*	5.9 \pm 0.9	6.2 \pm 0.9	0.07 \pm 0.06
	25	8	46.5 \pm 2.2	55.5 \pm 1.7*	5.9 \pm 0.5	4.1 \pm 0.7*	0.88 \pm 0.26*
TNF α_{31-45}	25	10	40.7 \pm 1.8	45.8 \pm 2.2*	6.2 \pm 0.6	4.6 \pm 0.6	0.27 \pm 0.17
TNF α_{46-65}	25	10	44.7 \pm 1.8	47.8 \pm 2.4	5.0 \pm 0.6	4.1 \pm 0.5	0.46 \pm 0.11*
TNF α_{31-68}	5	5	43.9 \pm 1.4	44.1 \pm 1.1	10.8 \pm 0.4	5.6 \pm 1.2*	0.29 \pm 0.10*
	25	7	45.8 \pm 1.5	54.8 \pm 2.5*	9.8 \pm 0.7	5.8 \pm 0.6*	0.96 \pm 0.14*
TNF α_{10-69}	5	4	50.3 \pm 2.9	53.9 \pm 0.8	6.3 \pm 1.2	4.4 \pm 1.1*	n/a
	10	4	54.5 \pm 4.2	62.7 \pm 4.2*	3.6 \pm 0.8	3.0 \pm 1.0	n/a
	100	3	57.9 \pm 2.5	63.2 \pm 4.8	10.8 \pm 1.8	7.0 \pm 1.8	n/a
TNF α_{44-68}	25	7	47.1 \pm 1.3	52.3 \pm 2.3	10.6 \pm 0.6	8.5 \pm 0.8*	0.52 \pm 0.12*
TNF α_{69-100}	1	4	44.9 \pm 1.6	47.4 \pm 2.4	10.3 \pm 1.3	5.4 \pm 0.7	-0.19 \pm 0.18
	5	9	45.2 \pm 1.8	45.1 \pm 1.9	8.2 \pm 0.9	6.5 \pm 0.8	0.59 \pm 0.13*
	25	8	48.2 \pm 1.5	49.6 \pm 2.1	7.8 \pm 1.1	6.2 \pm 0.7	0.76 \pm 0.11*
TNF $\alpha_{101-135}$	25	7	45.6 \pm 1.7	42.9 \pm 3.5	8.2 \pm 1.1	7.1 \pm 0.8	0.06 \pm 0.10
TNF $\alpha_{140-157}$	10	4	56.1 \pm 2.4	56.7 \pm 4.6	3.5 \pm 0.3	4.2 \pm 1.1	n/a
	100	4	49.4 \pm 1.1	54.1 \pm 2.0	4.4 \pm 0.3	4.2 \pm 0.5	n/a
F-MLP	10 pmol	4	47.1 \pm 1.8	49.2 \pm 1.9	5.8 \pm 0.4	5.0 \pm 0.8	n/a
	100 pmol	8	45.7 \pm 2.4	47.3 \pm 1.0	6.4 \pm 0.5	7.9 \pm 0.9	n/a

⁺The values indicate percent time spent in NREMS and REMS during the entire 6 h experimental period \pm SE. The effects on Tbr are expressed as the maximum 1 h average temperature changes in response to peptides. Asterisks indicate significant drug effects ($p < 0.05$).

Table 2: Effects of intravenous injection of pseudomurein or microspheres on rabbit SWS, REMS, EEG δ voltage, and T_{co}

dose	n	SWS		REMS		EEG δ Voltage	
		Contr	Exper	Contr	Exper	Contr	Exper
mg							
1-2	4	44 \pm 2	51 \pm 3	3.0 \pm 0.4	4.2 \pm 0.8	83 \pm 2	93 \pm 6
4	4	47 \pm 2	56 \pm 2***	6.5 \pm 0.8	5.8 \pm 0.6	68 \pm 9	81 \pm 9***
Polymyxin B pre-treatment							
2-4.5	8	46 \pm 1	51 \pm 2*	3.7 \pm 0.4	4.8 \pm 0.4*	71 \pm 9	76 \pm 11*
injection of 5×10^9 microspheres							
	4	47 \pm 2	50 \pm 1	6.5 \pm 0.8	4.3 \pm 0.1	68 \pm 9	67 \pm 9

Values are means \pm SEM. Sleep values are 6-h post-injection averages; n, no. of rabbits; SWS, slow-wave sleep; REMS, rapid-eye-movement sleep; EEG δ voltage, electroencephalographic δ -wave voltage [μ V]; T_{co} , colonic temperature 6-h post-injection; * $P < 0.05$, *** $P < 0.01$ Wilcoxon matched-pairs signed-ranks test.

TABLE 3: Effects of PGE₂ on Rabbit Sleep

dose nmol	N	% NREMS ⁺		% REMS ⁺	
		Cont	Expt	Cont	Expt
0.25	7	51.6 ± 1.9	54.0 ± 1.1	9.2 ± 0.7	7.5 ± 0.8
2.5	5	50.6 ± 3.1	50.8 ± 1.5	6.8 ± 1.0	5.6 ± 0.9
5.0	5	52.7 ± 3.8	48.6 ± 3.1	7.2 ± 0.8	6.5 ± 0.4
10.0	15	48.1 ± 1.4	48.5 ± 1.2	9.5 ± 0.7	7.3 ± 0.7

⁺ Average values of the 6-hr recording periods ± SE.

TABLE 4: Effects of PGD₂ on Rabbit Sleep

dose nmol	N	% NREMS ^a		% REMS ^a	
		Cont	Expt	Cont	Expt
0.25 ^{bc}	4	44.7 ± 2.0	45.3 ± 2.9	6.2 ± 1.1	8.1 ± 0.5
0.5 ^c	8	41.7 ± 2.4	43.8 ± 1.4	6.5 ± 0.5	8.0 ± 1.7
5.0 ^d	7	43.5 ± 1.7	44.2 ± 1.8	7.9 ± 1.7	5.9 ± 1.7
10.0 ^d	7	43.5 ± 1.7	42.2 ± 1.8	7.9 ± 1.7	6.1 ± 1.8
20.0 ^d	6	43.3 ± 1.9	46.0 ± 3.7	5.1 ± 1.9	5.9 ± 2.0
50.0 ^c	6	43.4 ± 2.8	48.2 ± 3.4	7.1 ± 0.7	6.1 ± 2.0
500.0 ^c	7	43.4 ± 2.5	45.1 ± 1.3	7.8 ± 0.9	10.7 ± 1.8

^a Average values of the six hour recording periods ± SE.

^b This dose was infused over a 45 min period prior to time 0; other doses were injected ICV over a 1 min period.

^{cd} PGD₂ used from Sigma^d and two different lots ^c from Cayman.

TABLE 5. The effects of saline and CCK injections on the maximal EEG delta wave amplitudes during NREMS in the first postinjection hour

dose	route	n	saline ⁺	CCK
0.05 µg	icv	7	306.9 ± 22.2	303.6 ± 27.2
0.5 µg	icv	9	306.3 ± 27.3	232.7 ± 18.3
2 µg	icv	5	259.5 ± 26.0	284.8 ± 33.1
2.5 µg/kg	ip	11	300.1 ± 13.3	287.2 ± 17.5
10 µg/kg	ip	4	316.1 ± 5.5	280.8 ± 18.6
40 µg/kg	ip	7	266.2 ± 22.4	259.9 ± 19.4

⁺ The values represent average maximal delta wave amplitudes in µV ± SE

Table 6

Summary of effects of substances tested on HLA_{DR} expression

Agents		Dose range	Incubation	Cell lines used	Effect
rhIFN γ		0.1-5 10 ³ U/ml	4 days	HTB14	↑
		0.1-5 10 ³ U/ml	4 days	HTB16	↑
		0.1-10 ⁴ U/ml	4 days	HTB17	↑
		0.1-10 ² U/ml	4 days	HTB11	—
rhTNF α		0.1-250 ng/ml	4 days	HTB16	—
+rhTNF α	+rhIFN γ^{++}	0.1-250 ng/ml	4 days	HTB16	↑
	(100 U/ml)				
rhTNF	+rhIFN γ	0.1-250 ng/ml	4 days	HTB16	↑
	(500 U/ml)				
TGF β 1		0.01-10 ng/ml	6 days	HTB16	—
TGF β 1	+rhIFN γ	0.01-10 ng/ml	6 days	HTB16	↓
	(100 U/ml)				
TGF β 1	+rhIFN γ	0.01-10 ng/ml	6 days	HTB16	↓
	(500 U/ml)				
TGF β 2		0.01-10 ng/ml	6 days	HTB16	—
TGF β 2	+rhIFN γ	0.01-10 ng/ml	6 days	HTB16	↓
	(100 U/ml)				
TGF β 2	+rhIFN γ	0.01-10 ng/ml	6 days	HTB16	↓
	(500 U/ml)				

Table 6 (cont.)

rhIL1 β		0.5-250 pg/ml	4 days	HTB16	—
rhIL1 β	+rhIFN γ (500 U/ml)	0.5-250 pg/ml	4 days	HTB16	↓
PGE $_2$		10 $^{-9}$ -10 $^{-5}$ M	4 days	HTB16	—
PGE $_2$	+rhIFN γ (500 U/ml)	10 $^{-9}$ -10 $^{-5}$ M	4 days	HTB16	↓
PGD $_2$		10 $^{-9}$ -10 $^{-5}$ M	4 days	HTB16	—
PGD $_2$	+rhIFN γ (500 U/ml)	10 $^{-9}$ -10 $^{-5}$ M	4 days	HTB16	—
IFN α		1-10 3 U/ml	4 days	HTB16	—
IFN α	+rhIFN γ (500 U/ml)	1-10 3 U/ml	4 days	HTB16	—
VIP		10 $^{-8}$ -10 $^{-5}$ M	4 days	HTB16	—
VIP	+rhIFN γ (500 U/ml)	10 $^{-8}$ -10 $^{-5}$ M	4 days	HTB16	—
DSIP		10 $^{-8}$ -10 $^{-5}$ M	4 days	HTB16	—
DSIP	+rhIFN γ (500 U/ml)	10 $^{-8}$ -10 $^{-5}$ M	4 days	HTB16	—
5-HT		10 $^{-8}$ -10 $^{-5}$ M	4 days	HTB16	—
5-HT	+rhIFN γ (500 U/ml)	10 $^{-8}$ -10 $^{-5}$ M	4 days	HTB16	—

Table 6 (cont.)

Hydrocortisone	10 ⁻⁵ -10 ⁻³ M	4 days	HTB16	—
Hydrocortisone	10 ⁻⁵ -10 ⁻³ M	4 days	HTB16	—
+rhIFN γ (500 U/ml)				
MDP	0.01-10 ug/ml	7 days	HTB16	—
MDP	+rhIFN γ 0.01-10 ug/ml	7 days	HTB16	—
(500 U/ml)				

+ \uparrow indicate increase, — no effect, and \downarrow decrease in HLA_{DR} expression. ++When a substance was used in combination with IFN γ , direction of effects are relative to those observed with IFN γ alone.

TABLE 7. List of putative sleep factors (NREMS factors, REMS sleep factors, or both) and putative waking factors.

Sleep Factors	References
<p>I. <u>Identified</u> Delta sleep-inducing factor (DSIP) Arginine vasotocin (AVT) Vasoactive intestinal peptide (VIP) Growth hormone-releasing factor/peptide (GRF) Somatostatin (SRIF) Growth hormone (GH) Cholecystokinin (CCK) Insulin Desacetyl-alpha-melanocyte-stimulating hormone (desacetyl-alpha-MSH) Corticotropin-like intermediate lobe peptide (CLIP) Neuropeptide Y Interleukin-1 (IL1) Interferon alpha-2 (IFNα_2) Tumor necrosis factor (TNF) Muramyl peptides (MPs) Lipid A Prostaglandin D₂ Steroid hormones and metabolites Serotonin (5-HT) Melatonin Uridine (SPS-A-1) Adenosine Oxidized Glutathione (GSSG)</p>	<p>Schoenenberger, 1984; Graf and Kastin, 1984 Pavel, 1979 Drucker-Colin, <i>et. al.</i>, 1984; Riou, <i>et. al.</i>, 1982 Obál, 1986; Ehlers, <i>et. al.</i>, 1986 Danguir, 1986 Drucker-Colin, <i>et. al.</i>, 1975 Mansbach and Lorenz, 1983; Kapás, <i>et. al.</i> 1988 Danguir and Nicolaidis, 1984 Chastrette and Cespuglio, 1985 Chastrette and Cespuglio, 1985; Chastrette, <i>et. al.</i>, 1990 Zini, <i>et. al.</i>, 1984 Krueger, <i>et. al.</i>, 1984 Krueger, <i>et. al.</i>, 1987 Shoham, <i>et. al.</i>, 1987 Krueger, <i>et. al.</i>, 1982 Cady, <i>et. al.</i>, 1989 Hayaishi, 1988 Heuser, <i>et. al.</i>, 1967 Jouvet, 1984; Koella, 1984 Datta and King, 1980 Inoué, <i>et. al.</i>, 1984 Radulovacki and Virus, 1985 Honda, <i>et. al.</i>, 1990</p>
<p>II. <u>Unidentified</u> Motor activity-reducing factor REM sleep factor PS (paradoxical sleep)-inducing factor Peptide-like urinary sleep factor</p>	<p>Borbély and Tobler, 1980 Sallanon, <i>et. al.</i>, 1985 Adrien and Dugovic, 1985 Ursin, 1984</p>
Waking Factors	
<p>I. <u>Identified</u> Alpha-melanocyte-stimulating hormone (alpha-MSH) Corticotropin-releasing factor/adrenocorticotrophic hormone (CRF/ACTH) Thyrotropin-releasing hormone (TRH) Endogenous opioids Prostaglandin E₂ Interleukin-1 receptor antagonist (IL1ra)</p>	<p>Opp, <i>et. al.</i>, 1988 DeWied, <i>et. al.</i>, 1976; Ehlers, <i>et. al.</i>, 1986, Opp, <i>et. al.</i>, 1989 Takahashi, <i>et. al.</i>, 1985 Dzolic <i>et. al.</i>, 1985 Hayaishi, 1988 Opp and Krueger, in press</p>
<p>II. <u>Unidentified</u> Factor E Motor activity-enhancing factor</p>	<p>Fencl, <i>et. al.</i>, 1971 Sachs, <i>et. al.</i>, 1976</p>

*Updated reviews are cited where possible.

TABLE 8. Criteria for NREMS Factors with Regard to Physiological Sleep

1. A NREM-SF should induce increased incidence and/or duration of NREMS.
 2. A NREM-SF should reduce the latency to NREMS during periods of maximum effects.
 3. A SF should have different quantitative effects at different times of the circadian day.
 4. A NREM-SF should enhance EEG slow wave amplitudes.
 5. Sleep structure should be maintained, although altered duration of NREMS and/or REM sleep may occur; *i.e.*, it should still cycle through stages of W, NREMS, and REM.
 6. The enhanced NREMS induced by a SF should be readily reversible by appropriate stimuli.
 7. Behavior following appropriate doses of SF should be normal.
 8. Autonomic changes, *e.g.*, brain temperature changes, that are tightly coupled to sleep states, should persist after SF treatment.
-

TABLE 9. Criteria for Sleep Factors

- A. Testable criteria:
 1. The SF should induce and/or maintain physiological sleep (see Table 8).
 2. The SF should be present in the animal.
 3. The concentration and/or turnover of the SF and/or the concentration and/or turnover of its receptor and/or its receptor regulators should vary with the state of vigilance.
 4. The SF should be chemically defined.
 5. A dose-effect relationship for the SF should prevail within a certain dosage range.
 6. The range of biological activities should be similar across species.
- B. Criteria that should apply as our knowledge of sleep is expanded:
 1. A SF should act directly on those brain mechanisms responsible for sleep.
 2. Inactivation of SFs (at the production or receptor level) should result in insomnia.




Fig. 1. Effects of intravenous injection of 4 mg pseudomurein in 1 ml PFS (filled circles) or vehicle (1 ml PFS into same rabbits on different days; open circles) on rabbit slow-wave sleep (SWS) (A), rapid-eye-movement sleep (REMS) (B), δ -wave amplitudes (C), and brain temperatures (D). A, B, C. hourly averages for indicated hour. D: differences from control recording (ΔT_{br}). $n = 4$. Data points are means \pm SEM. SWS and EEG δ voltage were increased during post-injection hours 1 through 4. REMS was not affected. T_{br} was transiently increased with a peak 1.5 hours post-injection.




Fig. 2. Effects of intracerebroventricular injection of PGE₂ on brain temperature of rabbits. Values are the hourly means (\pm SEM) for the following PGE₂ doses: 0.25 nmol (circles; N = 5); 2.5 nmol (squares; N = 5); 5.0 nmol (triangles; N = 5), 10.0 nmol (diamonds; N = 7). PGE₂ induced dose-related increase in brain temperature that were confined to the first two hours postinjection.




Fig. 3. Effects of intracerebroventricular injection of PGE₂ on NREMS and REMS duration in the first postinjection hour. Each data point represents the mean (\pm SEM) of 5-15 rabbits after control vehicle injections (open circles) or after PGE₂ (closed circles). * denote significant departure from control (Wilcoxin; $p < 0.05$).




Fig. 4. Effects of intracerebroventricular injection of PGD₂ on duration of NREMS and REMS during the first postinjection hour. Each data point is the mean (±SEM) of 6-8 rabbits expressed as percent recording time after control vehicle (open circles) or after PGD₂ (closed circles). There were no significant changes in NREMS or REMS duration after injection of PGD₂.




Figure 5. The effects of ip injection of various doses of cholecystokinin (CCK, filled symbols) and saline (open symbols) on sleep-wake activity and brain temperature. The injections were done at time "0". Error bars indicate SE, asterisks indicate significant differences between the effects of CCK and saline (paired Student's t-test, $p < 0.05$). The highest dose of CCK induced an enhancement of NREMS for about 1 h.




Figure 6. The effects of icv injection of various doses of CCK and saline on sleep-wake activity and T_{br} . See legend to Fig. 5 for details. Unlike high doses of CCK injected ip, icv CCK failed to enhance sleep.




Figure 7. Growth curves of glioblastoma cell lines HTB14 (top panel), HTB16 (middle panel) and HTB17 (bottom panel), and the correlation between cell number and protein amount. Cells were seeded in 96-well plates; cell number and protein amount were determined every day for 11 days. Each point shows the mean and standard deviations from 6 replicate wells. (●) indicates cell number/cm²; (○) indicates protein amount determined from wells parallel to the wells giving cell number.




Figure 8. rhIFN γ -induced HLA α expression in glioblastoma and neuroblastoma cell lines after incubation with various concentrations of rhIFN γ for 4 days. HLA α expression is presented as OD/mg protein. Data are shown as mean + standard deviations from 6 replicate wells. An * indicates significant difference from the control value of HLA α expression obtained from the cells incubated with culture medium.




Figure 9. Time course response of rhIFN γ -induced HLA-DR expression in glioblastoma cell line HTB16. (●) indicates cells were incubated with culture medium. (○) indicates cells were incubated with 1000 U/ml of rhIFN γ . Media containing rhIFN γ were removed on day 5, and replaced with fresh culture medium, and HLA-DR expression was assessed every day. HLA-DR expression is presented as OD/mg protein. rhIFN γ -induced HLA-DR expression is noticed on day 3, reaches peak on day 5, and still detectable two days after the removal of rhIFN γ from culture media. Data are obtained from triplicate wells.




Figure 10. Effects of rhTNF α and anti-TNF α on rhIFN γ -induced HLA_{DR} expression in HTB16 cells. HLA_{DR} expression is presented as OD/mg protein; data are shown as means + SD from 6 replicate wells. Upper panels; cells were incubated with various concentrations of rhTNF α combined with 100 (solid bars) or 500 U/ml (open bars) of rhIFN γ for 4 days. An * indicates significant difference from the control values obtained in the presence of either 100 or 500 U/ml of rhIFN γ . Lower panel; anti-TNF α blocked synergistic effect of rhTNF α on rhIFN γ -induced HLA_{DR} expression. Cells were incubated with 100 U/ml of rhIFN γ only (first column), combined with 10 ng/ml of rhTNF α (second column), and 100 U/ml of rhIFN γ combined with 10 ng/ml of rhTNF α plus various concentrations of anti-TNF α for 4 days. Anti-TNF α at a dose of 10 mg/ml was sufficient to completely block the effects of rhTNF α . An * indicates significant difference from the value obtained from wells incubated with 100 U/ml of rhIFN γ + 10 ng/ml of rhTNF α .




Figure 11. Time course response of the effects of rhTNF α and TGF β 1 and β 2 on rhIFN γ -induced HLA-DR expression in HTB16 cells. HLA-DR expression is presented as OD/mg protein; data are shown as means + SD from 6 replicate wells. Upper panel; cells were incubated with culture medium (open bars), 100 U/ml of rhIFN γ (solid bars), and 100 U/ml of rhIFN γ combined with 10 ng/ml of rhTNF α (crosshatched bars) for 8 days. The effects of TNF α were noticed after 24 hour incubation, reached peak on day 4, and still detectable on day 8. An * indicates significant difference from the values obtained in the presence of 100 U/ml of rhIFN γ on the same day. Time course response of inhibitory effect of porcine TGF β 1 and β 2 on rhIFN γ -induced HLA-DR expression (lower panel). Lower panel; cells were incubated with culture medium (open bars), 100 U/ml of rhIFN γ (solid bars), and 100 U/ml of rhIFN γ combined with 10 ng/ml of either TGF β 1 (crosshatched bars) or TGF β 2 (hatched bars). The effects of TGF β 1 and β 2 were detectable on day 5 of incubation, reached maximal level on day 7, and remained on day 8. An * indicates significant difference from the values obtained in the presence of 100 U/ml of rhIFN γ only on the same day.




Figure 12. Effects of TGFβ1 and anti-TGFβ on rhIFNγ-induced HLA_{DR} expression in HTB16 cells. Upper panel, cells were incubated with various concentrations of TGFβ1 in the presence of 100 U/ml (solid bars) or 500 U/ml (open bars) of rhIFNγ for 6 days. An * indicates significant difference from the values obtained in the presence of either 100 or 500 U/ml of rhIFNγ. Lower panel, anti-TGFβ1 blocked the inhibitory effects of TGFβ1 on IFNγ-induced HLA_{DR} expression. Cells were incubated with 100 U/ml of rhIFNγ only (first column), 100 U/ml of rhIFNγ combined with 10 ng/ml of TGFβ1, and 100 U/ml of rhIFNγ combined with 10 ng/ml of TGFβ1 plus various concentrations of anti-TGFβ for 6 days. An * indicates significant difference from the value obtained in the presence of 100 U/ml of rhIFNγ and 10 ng/ml of TGFβ1.




Figure 13. Effects of TGFβ2 and anti-TGFβ2 on rhIFNγ-induced HLA_{DR} expression in HTB16 cells. HLA_{DR} expression is presented as OD/mg protein; data are shown as means + SD. Upper panel, cells were incubated with various concentrations of TGFβ2 in the presence of 100 (solid bars) or 500 U/ml (open bars) of rhIFNγ for 6 days. An * indicates significant difference from the values obtained in the presence of either 100 or 500 U/ml of rhIFNγ. Lower panel, anti-TGFβ2 blocked the inhibitory effects of TGFβ2 on IFNγ-induced HLA_{DR} expression. Cells were incubated with rhIFNγ (100 U/ml, solid bar in first column; 500 U/ml, open and crosshatched bars in first column), rhIFNγ (100 U/ml) combined with 1 ng/ml of TGFβ2 and various concentrations of anti-TGFβ2 (solid bars), and rhIFNγ (500 U/ml) combined with 1 ng/ml of TGFβ2 plus various concentrations of anti-TGFβ2 (open bars) or 10 ng/ml of TGFβ2 plus various concentrations of anti-TGFβ2 (crosshatched bars) for 6 days. An * indicates significant difference from the values obtained in the presence of either 100 or 500 U/ml of rhIFNγ, combined with either 1 or 10 ng/ml of TGFβ2 (second column).




Figure 14. Effects of rhIL-1 β and PGE₂ on rhIFN γ -induced HLA-DR expression in HTB16 cells. HLA-DR expression is presented as OD/mg protein; data are shown as means + SD. Upper panel, cells were incubated with various concentrations of rhIL-1 β in the presence of 500 U/ml of rhIFN γ for 4 days. An * indicates significant difference from the basal value obtained in the presence of 500 U/ml of rhIFN γ . Lower panel, PGE₂ inhibited rhIFN γ -induced HLA-DR expression. Cells were incubated with various concentrations of PGE₂ in the presence of 500 U/ml of rhIFN γ for 4 days. An * indicates significant difference from the value obtained in the presence of 500 U/ml of rhIFN γ .




Figure 15: Activational system for sleep indicating possible interactions between putative SFs (left side) and the effects of those SFs on sleep (right side). Some of the interactions shown have been tested using sleep as the assay end point. For example, the CRF/ACTH, α MSH/glucocorticoid inhibiting actions on sleep may be related to their inhibitory effects on IL1 production or activity. Similarly, during infection when the supplies of muramyl peptides, endotoxin or viral dsRNA are enhanced, it is likely that sleep is enhanced via the ability of the microbial-derived substances to enhance cytokine production. See Table 7 for abbreviations used. Left lines; → indicates stimulation and ⊣ indicates inhibition. Arrows on right indicate sleep effects; ↑ increases, ↓ decrease and — no effect on sleep.




Figure 16: Sleep factors with multiple activities may selectively alter sleep by differentially interacting with various neuronal sets. The interactions may involve changes in intrinsic properties of the neurons involved. Each neuronal set has its own dynamic range of outputs affecting specific physiological systems. The involvement of any one set of neurons in sleep at any specific time is dependent upon which physiological system (SFs) are driving sleep.

DISTRIBUTION LIST

5 copies Director
Walter Reed Army Institute of Research
Walter Reed Army Medical Center
ATTN: SGRD-UWZ-C
Washington, DC 20307-5100

1 copy Commander
U.S. Army Medical Research and Development Command
ATTN: SGRD-RMI-S
Fort Detrick, Frederick, MD 21702-5012

2 copies Defense Technical Information Center (DTIC)
ATTN: DTIC-FDAC
Cameron Station
Alexandria, VA 22304-6145

1 copy Dean
School of Medicine
Uniformed Services University of the Health
Sciences
4310 Jones Bridge Road
Bethesda, MD 20814-4799

1 copy Commandant
Academy of Health Sciences, U.S. Army
ATTN: AHS-CDM
Fort Sam Houston, TX 78234-6100